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Executive Summary
Background
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the development of clinical practice guidelines
(CPGs) for nearly 3 decades, based on the shared vision of
their responsibility to provide guidance to cardiovascular
healthcare professionals and the patients they serve by
translating the best available evidence into clinical practice.
The ACCF/AHA Task Force on Practice Guidelines
(Task Force) oversees and directs the CPG development
process and methodology that have been the foundation of
our documents and responsible for their widespread recog-
nition. In brief, once a topic is selected for a new, revised, or
updated CPG, selected organizations and professional so-
cieties with similar interests and expertise are invited to
participate as partners or collaborators, with the overall
ACCF/AHA policy of being inclusive and collaborative.
Next, a guideline writing committee (GWC) chair is
selected by the Task Force, and together with the chair,
potential GWC members are identified, based on a detailed
and specific relationship with industry and other entities
(RWI) policy stating that the chair and the majority of
GWC members must have no relevant RWI. Once formed,
the GWC outlines the content of the document, performs a
detailed and specific evidence acquisition and review, drafts
recommendations with limited preliminary text, and attends
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CPGs where recommendations are vetted and reconciled
across existing guidelines. After the conference, the
document is finalized. Every recommendation is voted on
by each GWC member with appropriate recusal based on
relevant RWI. The finished document then undergoes
extensive peer review and response, and any recommen-
dation that is changed is voted on again by each GWC
member. The final document is reviewed, potentially
revised and approved by the Task Force, and sent to the
ACCF Board of Trustees, the AHA Science Advisory
and Coordinating Committee, and partnering or collab-
orating organizations for final approval. After this very
thorough and robust process, the CPG has essentially
been vetted throughout the academic and clinical com-
munity and is jointly published in the Journal of the
American College of Cardiology and Circulation. Once
ublished, it serves as official policy of both organiza-
ions, informing strategic initiatives, advocacy, programs,
roducts, and services.
Of critical importance is the continual evolution of the
evelopment process and methodology that has character-
zed the ACCF/AHA CPGs and the ongoing challenge to
imely respond to and integrate the continuous stream of
ew knowledge.
Commissioned by the U.S. Congress as part of the
edicare Improvement for Patients and Providers Act of
008 to set standards for CPGs, the Institute of Medicine
IOM) issued 2 reports: “Clinical Practice Guidelines We
an Trust” (1) and “Finding What Works in Health Care:
tandards for Systematic Reviews” (2) in March 2011. The
OM redefined CPGs as follows:
“Clinical practice guidelines are statements that include recom-
mendations intended to optimize patient care that are informed
by a systematic review of the evidence and an assessment of the
benefits and harms of alternative care options.” (1, p. 29)
The underpinnings of this definition are that a CPG should
be based on a systematic review (SR) of existing evidence; be
developed by a knowledgeable, multidisciplinary panel of
experts and key stakeholders; consider important patient
subgroups and preferences as appropriate; be based on a
transparent process that minimizes conflicts of interest and
biases; provide a clear explanation of the logical relation-
ships between alternative care options and health outcomes;
provide the ratings of both the strength of the recommen-
dation and the quality of evidence; and be revised as
appropriate based on new evidence (1,2).
In view of IOM reports and the ACCF/AHA ongoing
improvement processes, the Task Force commissioned 5
Workgroups to address the IOM recommendations and
present their findings at a Methodology Summit.
Workgroup Charge
Each Workgroup was charged with reviewing each IOM
standard and supporting elements with respect to theWorkgroup topic; reviewing the current ACCF/AHA
CPGmethodology that addresses the standard; understand-
ing the gaps and potential barriers between the proposed
standard and the current method; and proposing recom-
mendations for the Task Force to incorporate and/or to
maintain or change existing methodology.
Workgroup Process
The 5 Workgroups were commissioned in August 2011 and
worked by teleconference to draft the preliminary report.
Each Workgroup focused on a series of questions to address
the specific standards proposed by the IOM. The IOM
reports were vetted by using a table (see Appendix 2) that
presented each of the proposed 21 standards and 82 sup-
porting elements, the existing applicable ACCF/AHA
CPG methodology, and the Workgroup’s proposal related
to the standard. Each Workgroup report consisted of a brief
introduction with an overview of the section content and
questions, the complete table, a discussion of the salient
issues and challenges that the Workgroup addressed, and
preliminary recommendations.
The Workgroups’ reports were distributed before the
Summit, which was held over 2 days in mid-December
2011. Each report was discussed by the conference attendees
and revised by the Workgroups with revisions and final
recommendations presented again to the full group. The
near-final draft report of each Workgroup was completed by
the close of the Summit.
After the Summit, the reports were finalized and then
edited for consistency. The completed “ACCF/AHA Clin-
ical Practice Guideline Methodology Summit Report” was
reviewed by the Task Force at its semiannual meeting in
June 2012. Priorities, resources, implementation, and oper-
ational issues were discussed. After this meeting, additional
minor edits were made, and the Report was reviewed and
accepted by the leadership of both the ACCF and the AHA
in September 2012.
Featured Additions to Existing Methodology
Inclusion of Patient Representatives
Fortified by the AHA’s focus on the patient and the public
it serves and its lay membership, and by the ACCF’s current
initiative on patient-centered care, the Task Force will
invite patient representatives (defined as patients and former
patients, patient advocates, or patient/consumer organiza-
tion representatives) to participate as a member of the Task
Force and a GWC. Methods to identify, select, train, and
manage RWI and intellectual perspectives of patient repre-
sentatives are proposed. Patient representatives will partic-
ipate in topic selection, patient choices, values, preferences,
and shared decision making.
Evidence Review Committee
The current CPG creation process will expand to include a
separate evidence review committee (ERC), tasked with the
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the scientific CPG. When appropriate, other stakehold-
ers (e.g., policy makers and payers) will be invited to
participate as members of the ERC. The ERC will be
responsible for all phases of the SR process, including the
identification, abstraction, and quality assessment of the
evidence base.
Systematic Review Using Standardized Protocols
The ACCF/AHA methodology will incorporate a formal
SR of the evidence, initially, with a focused approach to a
confined topic. Standardized protocols may serve to stream-
line and enhance the process by developing topic-specific
questions that guide the direction of the SR (e.g., search for
studies, data extraction, synthesis, and presentation of find-
ings). The use of a PICO(TS) format (mnemonic: popula-
tion, intervention, comparator, outcomes, timing, and set-
ting) will be used to develop evidence question(s) for the
CPG SR.
Intellectual and Practice Perspectives
The current ACCF/AHA CPG process includes a de-
tailed and specific RWI policy and overall mandate to
ensure balance (race, ethnicity, sex, and intellectual
expertise and experience) among the GWC. In addition,
the concept of intellectual and practice perspective (the
latter term is operative when an individual’s income is
enhanced by performing a specific test or procedure
relevant to the guideline topic) will be defined, recog-
nized, and managed. Similar to the ACCF/AHA choice
of the term RWI rather than COI (conflict of interest)
related to industry, the ACCF and AHA have chosen the
terms intellectual perspective and clinical practice perspective
(rather than bias) to denote intellectual and practice-
related opinions and expertise based on evidence and/or
experience.
Expanded Review Process
An expanded group of external reviewers will be added to
the extensive peer review process for the completed CPG
before publication. The current review process includes
scientific and clinical content experts as well as partnering
and collaborating organizations and other related profes-
sional societies. External reviewers will comprise a full
spectrum of relevant stakeholders, including public repre-
sentatives and constituencies such as governmental agencies
(e.g., the Agency for Healthcare Research and Quality
[AHRQ] and the U.S. Food and Drug Administration
[FDA]). Moreover, the SR protocol and completed evi-
dence review will be opened to public comment. However,
because of the ability to introduce potential interference and
bias that cannot be adequately controlled or managed, the
completed CPG will not be subject to public comment
before publication.Workgroup Recommendations
(See Full Report for Complete List)
Workgroup 1: Clinical Practice Guidelines
We Can Trust
1. At least 1 patient representative should be a full voting
member of the Task Force and of a GWC. Patient
representatives could include patients, former patients,
members of patients’ families, caregivers, and laypeople
with “health literacy,” including scientists, statisticians,
engineers, and science writers.
2. All nonprofessional members of a GWC should avail
themselves of the U.S. Cochrane Center and Consumers
United for Evidence-Based Medicine’s “Understanding
Evidence-Based Healthcare: A Foundation for Action”
or an equivalent online learning module before accepting
their position.
3. Patient representatives’ responsibilities should include
the formulation of key clinical questions; topic selection;
patient choices, values, and preferences; and issues sur-
rounding quality of life. Patient representatives should be
encouraged to provide input on the selection of diagnos-
tic tests and treatment modalities.
4. CPGs should be provided to an expanded group of
external reviewers before publication. External reviewers
would comprise a full spectrum of relevant stakeholders
(in addition to the current group of scientific and clinical
content experts, as well as to partnering, collaborating,
and other relevant professional societies), such as health-
care specialty societies, agencies (e.g., federal govern-
ment), and representatives of the public.
5. The ACCF/AHA CPG development policy should be
expanded to incorporate intellectual and clinical practice
perspectives. This information is discussed by the Task
Force during GWC formulation, and the expertise of the
members is noted in the guideline section on writing
committee composition. This review and selection pro-
cess should be made transparent to the GWC during
their orientation meeting/teleconference, and GWC
members should be asked to verbally update the group if
any changes occur. For specific CPGs, consideration
should be given to capturing clinical practice perspectives
on the author RWI disclosure table if the GWC mem-
ber’s income is enhanced by performing a specific test or
procedure that is relevant to the CPG topic.
Workgroup 2: Standards for Initiating
a Systematic Review
1. An ERC composed of content experts, methodologists,
statisticians, and other identified stakeholders (policy
makers and payers) should participate in the creation of
ACCF/AHACPGs (initially, with a focused approach to a
confined topic). The ERC will interact with members of
the GWC; however, the responsibilities of the ERC will
be separate, distinct, independent, and clearly delineated.
217JACC Vol. 61, No. 2, 2013 Jacobs et al.
January 15, 2013:213–65 ACCF/AHA Guideline Methodology Summit Report2. In an effort to standardize the process by which ACCF/
AHA CPGs are created, the PICO(TS) format should
be applied to develop the SR questions. It will be the
responsibility of the ERC to create the format of the SR.
3. The current peer review process of ACCF/AHA CPGs
should be expanded to include a formal peer assessment
of the SR protocol. External stakeholders and patients’
representatives should be included in this expanded
process, which will serve to enhance the applicability of
the document to real-world decision-making policies
and clinical scenarios.
Workgroup 3: Standards for Finding and
Assessing Individual Studies
1. The system and tool used for critical appraisal of each
study, currently under development by the Task Force
(ACCF/AHA Evidence Grading Tool), will be used in
the pilot SR conducted in conjunction with CPGs. In
this case, it is anticipated that the assessment of the
quality of the study will be focused within the context of
a PICO(TS) question.
2. The pilot system for critical appraisal of each study will
be composed of a quantitative assessment, a yes/no
assessment of key features of the studies, and a scoring of
each of the 3 domains identified by the IOM: risk of
bias, relevance, and fidelity of implementation.
3. The quantitative assessment will need some revision for
application to observational studies and for focused
assessment of the 3 domains identified by the IOM.
4. A scoring of the quality of the study in each of the 3
domains will be qualitatively accomplished by a judg-
mental scoring by the members of the ERC. The
domain, risk of bias, should be renamed “freedom from
bias” (or “internal validity”) so that the judgment system
is directionally similar for all 3 domains. For each of the
3 domains, which are 1) freedom from bias, 2) relevance,
and 3) fidelity of implementation, one of following
judgments will be assigned: fatally flawed, low (low
freedom from bias, low relevance, or low fidelity), inter-
mediate, or high. In addition, there will be a summary
assessment of each study: fatally flawed study, low-
quality study, intermediate-quality study, and high-
quality study.
5. For other studies being considered in other parts of
the CPG, a similar evaluation of the quality of the
individual studies may be done. It will be necessary,
however, for each proposed recommendation, to
clearly identify the population under consideration,
intervention, comparator, outcome, and setting, at
least in a broad and general way.
Workgroup 4: Standards for Synthesizing the
Body of Evidence
Workgroup Recommendations for Assessing and
Addressing the Quality of a Body of Evidence1. Standardize the method of assessment and description of
the quality of the body of evidence across studies and
perform a qualitative assessment of individual studies and
aggregated studies.
2. Depict qualitative assessment across studies addressing
the key elements for each PICO(TS) question in a
summary table.
3. Where appropriate, provide a risk-of-bias assessment
table across studies. This table would be similar to the
Cochrane format, which includes items such as random
sequence generator, allocation concealment, blinding of
participants and personnel, blinding of outcome assess-
ment, incomplete outcome data, selection report, or
other bias.
4. Generate standardized summary and evidence table tem-
plates specific to ACCF/AHA requirements.
5. When available, high-quality SRs from reputable orga-
nizations (e.g., the Cochrane Collaboration and AHRQ
evidence-based practice centers [EPCs]) should be used.
If a new SR is needed, resources will need to be secured
to pursue de novo analyses.
6. Notwithstanding these efforts to standardize and im-
prove the qualitative analysis of bodies of evidence, every
effort should be made to minimize delays in time for
guideline development/revision.
Workgroup Recommendations for Standards for Quantitative
Analysis (i.e., Meta-Analysis) Across a Body of Evidence
1. The GWC, in conjunction with the Task Force, should
determine when a specific meta-analysis is needed.
2. With statistical consultation, preferred, acceptable meth-
ods for meta-analysis (including a Bayesian analysis
when appropriate) should be defined in each instance.
3. When available, high-quality meta-analyses from repu-
table organizations (e.g., the Cochrane Collaboration
and AHRQ EPCs) should be used. If a new meta-
analysis is needed, resources should be secured to pursue
de novo analyses.
4. Notwithstanding efforts to standardize and improve the
approach to quantitative analyses across studies, every
effort should be made to minimize delays in time for
guideline development/revision.
Workgroup Recommendations for
ACCF/AHA Grading Methodology and Nomenclature
1. Retain the current basic ACCF/AHA Class of Recom-
mendation (COR) and Level of Evidence (LOE) struc-
ture/nomenclature.
2. Standardize how LOE: A, B, C are determined by using
a validated ACCF/AHA Evidence Grading Tool (under
development) that will incorporate features of existing
tools.
34
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(QOE) (once the ACCF/AHA Evidence Grading
Tool is operational).
4. Add a separate category for QOE: E (expert opinion) and
generate specific definitions and examples for QOE: E.
5. Change “Treatment Effect” on the COR/LOE table to
“Intervention Effect” and indicate that “Intervention”
includes medications, devices, therapeutic strategies,
procedures, diagnostic tests, and other.
6. Add adjectives that “map” COR/LOE to the National
Heart, Lung, and Blood Institute (NHLBI) (and Grad-
ing of Recommendations Assessment, Development and
Evaluation [GRADE]) (i.e., I [strong]; IIa [moderate];
IIb [weak]; III [against]).
Workgroup 5: Standards for Reporting
Systematic Review
1. An SR included in CPGs should be published as a
separate peer-reviewed manuscript(s) when feasible.
2. Recommendations supported by an SR should be iden-
tified in CPGs in addition to the appropriate COR and
LOE; for example: (Class I; LOE: A)SR.
. Within the CPG, salient tables and figures from the SR
should be included to support recommendations. The
remaining pieces of methodology will be hyperlinked to
the original SR publication. By doing so, key elements of
the SR will be available for public access after publication
of the CPGs.
. CPG review tables should be incorporated into CPGs
for non–SR-based recommendations and be available as
online supplemental tables.
. CPG review tables should incorporate most study com-
ponents that are provided in SR tables.
Future Directions
It is critically important that we continue to monitor the
impact of the proposed IOM standards and ACCF/AHA
Summit Workgroup recommendations on the overall time-
liness and usefulness of our CPGs, in addition to the
inherent resource consumption required. Most important
will be the ongoing assessment of the changes in method-
ology in relation to improved patient care and outcomes.
Yet to be determined is whether the inclusion of patients’
representatives in CPG development and performance of a
formal SR of the evidence will enhance the translation of
recommendations as anticipated. What is clear, however, is
that these changes have the potential to move us into the
future as we prepare to incorporate cost and value into our
CPG recommendations and to incorporate these recom-
mendations into electronic clinical support systems.
The overarching goal in the evolution of the process and
methods used to develop ACCF/AHA CPGs is to combine
an ever-expanding evidence base with multidisciplinary
expertise and experience while being mindful of patient
values so as to improve clinical decision making and thereby
improve the quality of care and outcomes for patients withcardiovascular disease. The ACCF and AHA remain stead-
fast in their commitment to this endeavor.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHAClinical Practice GuidelineMethodology Summit
Abbreviation List:
COR  Class of Recommendation
CPG  clinical practice guideline
EPC  evidence-based practice center
ERC  evidence review committee
GRADE  Grading of Recommendations Assessment,
Development and Evaluation
GWC  guideline writing committee
IOM  Institute of Medicine
LOE  Level of Evidence
PICO(TS) format  (mnemonic: population, interven-
tion, comparator, outcomes, timing, and setting)
QOE  Quality of Evidence
RCT  randomized controlled trial
RWI  relationship with industry and other entities
SR  systematic review
Full Report
Introduction
The American College of Cardiology Foundation (ACCF)
and American Heart Association (AHA) have jointly de-
veloped and published clinical practice guidelines (CPGs)
since the early 1980s, when, in response to a governmental
concern over the potential overutilization of pacemakers, the
ACCF and AHA were asked to evaluate the evidence and
provide recommendations for practice. In 1984, the
“ACCF/AHA Guidelines for Permanent Cardiac Pace-
maker Implantation” was published (3). Since then, the
guideline effort has continued to expand, and currently, the
ACCF/AHA Task Force on Practice Guidelines (Task
Force) oversees and directs 17 CPGs, the majority of which
are broadly disease based. In 2011, 2 revised, 2 new, and 3
focused updates to the CPGs were published.
The CPG development process and methodology con-
tinue to evolve. Over the past few years, several process
improvement initiatives resulted in CPGs that have limited
text and include evidence and summary tables. The writing
process includes a consensus conference where members of
multiple guideline writing committees (GWCs) meet to
reach consensus and concordance on overlapping recom-
mendations. Methodological enhancements include the de-
velopment and testing of a scoring tool to consistently assess
the quality of randomized controlled trials (RCTs) that
219JACC Vol. 61, No. 2, 2013 Jacobs et al.
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ian approaches to evidence synthesis. This continued evo-
lution is in response to the primary goal of providing
evidence-based guidelines for healthcare professionals
practicing cardiovascular medicine while maintaining
relevancy and ease of use at the point of care. The
recommendations are articulated in the time-honored
and widely recognized ACCF/AHA Class of Recom-
mendation (COR) and Level of Evidence (LOE) scheme.
Currently, we are working to incorporate patient prefer-
ence and shared decision making into the development
and translation of our CPG recommendations.
In March 2011, the Institute of Medicine (IOM) pub-
lished 2 reports, “Clinical Practice Guidelines We Can
Trust” (1) and “Finding What Works in Health Care:
Standards for Systematic Reviews” (2). There are 8 stan-
dards for developing trustworthy CPGs that include estab-
lishing transparency, managing conflict of interest, creating
multidisciplinary development groups, basing the CPG
recommendations on systematic reviews (SRs), establishing
evidence foundations for rating the strength of recommen-
dations, articulating recommendations, establishing meth-
ods for external review, and updating. It is noteworthy
that the ACCF/AHA CPGs were recognized as being
compliant with the majority of these standards (Work-
group 1 Comparison Table). However, in view of these
detailed reports and our ongoing challenge to respond to
the continuous stream of new evidence in a timely
manner while maintaining our robust processes for CPG
generation and approval, the Task Force decided to hold
a Methodology Summit that would focus on the stan-
dards for and performance of systematic evidence reviews
and on the inclusion of patients and consumers in the
CPG development process.
The purpose of this Methodology Summit was to com-
pare and contrast the current ACCF/AHA CPG method-
ology with the standards proposed by the IOM and consider
what, if any, changes or improvements should be imple-
mented to enhance our development process and evidence
review and evaluation. In August 2011, the Task Force
commissioned 5 Workgroups:
1. Clinical Practice Guidelines We Can Trust
2. Standards for Initiating a Systematic Review
3. Standards for Finding and Assessing Individual Studies
4. Standards for Synthesizing the Body of Evidence
5. Standards for Reporting Systematic Reviews
The invited members of each Workgroup, in addition to
guests at the Summit (and including all Task Force mem-
bers), brought a diversity of experience and expertise to this
initiative. Specifically, the membership included those with
special interest and experience in CPG development inde-
pendent of the ACCF/AHA in addition to those with
extensive experience in development of ACCF/AHA
CPGs. Participants also included methodologists, biostat-isticians, clinical and research cardiologists, epidemiologists,
and nurses.
Each Workgroup was charged with 1) reviewing the
IOM recommendations and sections of the current tools
available for developing/conducting SR relevant to its
topic; 2) comparing and contrasting the recommenda-
tions with current ACCF/AHA methodology, including
an analysis/discussion of the gaps and barriers; and 3)
drafting recommendations/considerations for changes
and improvements to the evidence review process and the
COR/LOE, including a discussion as to why changes
may or may not be implemented. The report of the
Workgroups follows.
Alice K. Jacobs, MD, FACC, FAHA
Immediate Past Chair, ACCF/AHA Task Force on Practice
Guidelines
1. Workgroup 1: Clinical Practice Guidelines
We Can Trust
See Workgroup 1 Comparison Table.
(Authors: Dr. Frederick G. Kushner, Chair; Drs. Ralph G.
Brindis, Mark A. Creager, Ralph L. Sacco, William A. Zoghbi,
and Mr. William H. Roach, Jr.)
The Task Force has recommendations for patient-centered
care within its methodology manual (4). GWC are encour-
aged to consider the role of patient preferences in decisions
with substantial personal choice or values and to consider
patient-specific modifiers, comorbidities, and issues of pa-
tient preference. The IOM report on “Clinical Practice
Guidelines We Can Trust” (Section 3.2 and Section 3.3) (1)
recommends the involvement of patients (or former pa-
tients) and the public (patient advocates, patient/consumer
organizations) in the CPG process to formulate clinical
questions and review draft CPGs. The IOM report also
recommends that strategies for training participants should
be adopted by guideline developers. Consumer involvement
may provide transparency and a means of establishing
relevancy and credibility for the application of evidence-
based medicine to patients and other stakeholders and
thereby dispel myths and fears through the mutual
understanding of issues and values for both patients and
providers. Consumers can be powerful allies as supporters
of quality initiatives. They can also provide an important
perspective from the patient’s point of view in areas of
uncertainty, where alternative options exist, or where
there are substantial gaps in evidence. Finally, consumer
involvement can provide valuable perspectives for en-
hancing shared decision making. Currently, there is a
paucity of evidence surrounding the process and impact
of integrating consumers into the CPG process. For the
purposes of this document, “consumers” will be referred
to as patient representatives.
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1. How can the Task Force and GWC identify the
appropriate “patient representative”? What are the
criteria to be met for selection of “patient representa-
tives” who serve? Will they be volunteers or con-
tracted for their work?
As defined by the Cochrane Consumer Network, consum-
ers (“patient representatives” herein) include all users or
receivers of health care, including patients, members of the
public, caregivers, family members, and members of con-
sumer advocacy groups. Several organizations have identi-
fied or are in the process of identifying individuals to serve
on GWC. The 4 largest of these are the Cochrane Collab-
oration through Cochrane Consumer Network and a U.S.
subsidiary, Consumers United for Evidence Based Medi-
cine, Agency for Healthcare Research and Quality
(AHRQ), Consumers Union, and Guidelines International
Network. Consumers Union is currently developing a list of
“qualified” patient representatives to serve on evidence-
based medical guideline committees under the auspices of a
grant from the American Institutes for Research/AHRQ.
They solicited interested parties from their subscriber base
of 300,000 and received 2,000 expressions of interest. The
AHA has a long history of inviting lay volunteers to serve on
its boards and committees, in mission and fundraising
activities, and in advocacy, and regularly recommends con-
sumer representatives to private and governmental panels
and committees. The American Society of Clinical Oncol-
ogy has included consumers on their GWCs. Patient
representatives with defined constituencies can be particu-
larly valuable because of their institutional involvement. On
the basis of the comments from Consumers Union and the
American Society of Clinical Oncology and discussions
among its members, Workgroup 1 recommends the follow-
ing principles concerning the identification of appropriate
patient representative candidates:
A. A job description, including desired and necessary
attributes and expectations, should be available to the
Task Force and GWC chairs and to organizations
that may recommend candidates.
B. The Task Force and GWC should seek nominations
for patient representatives from trusted organizations
with knowledge of the individual, such as the AHA,
ACCF, Consumers Union, Cochrane Collaboration,
and AHRQ.
C. Patient representative candidates and/or their spon-
soring organizations should submit their resumes,
curriculum vitae, or personal statements.
D. Patient representatives should be advised of the time
commitment and compensated for travel expenses
identical to physician and other Task Force and
GWC members.
E. Patient representative candidates, similar to all mem-
bers, should complete the relationships with industry
and other entities (RWI) disclosure.F. The Task Force and/or GWC chair or designee
should interview potential consumer candidates and
identify other conflicts where they exist.
G. The development of a questionnaire similar to those
used by major charitable organizations to elicit pos-
sible bias should be considered.
H. Prospective members should be required to confirm
that they will give precedence to ultimate patient
health, well-being, quality care, and value in their
input, deliberation, and voting.
I. Patient representatives, as is true for other members of
the GWC, must be sensitive to their role as impartial
members and not permit financial and nonfinancial
conflicts, including personal, intellectual, or organiza-
tional relationships to influence their judgment.
J. Patient representatives on GWCs should be engaged
in the formulation of key clinical questions, topic
selection, patient choices, values, preferences, and
issues surrounding quality of life. They should be
encouraged to provide input on the selection of
diagnostic tests and treatment modalities.
K. Patient representatives should be acknowledged as
members of the GWC at publication, and a complete
summary of their RWI should be provided. They
should be subject to the same RWI and recusal rules
as other members.
2. Specifically, how is the patient representative to be
integrated into the CPG process and/or peer review
and/or external stakeholder review? What expecta-
tions are there for patient representative involvement?
As a member of the Task Force, patient representatives
would assist in directing and overseeing CPG development
and establishing policy with a focus on issues such as shared
decision making, patient preference, value, translation, and
implementation. Patient representatives may be best suited
to participate in the initial work of the GWC, during the
formulation of key clinical questions, topic selection, and
outline development, and, particularly, to comment on the
translation and communication of CPGs to the general
public. They may not be as helpful or comfortable with SR
or assignment of COR and LOE to specific recommenda-
tions. Patient representatives with certain technical skills
such as science journalists and writers may aid in a patient-
provider communication and summary section. Patient
representatives should be expected to contribute key ques-
tions to be answered by the GWC. They should provide
input about patient choices, values, preferences, and issues
surrounding quality of life in selecting diagnostic modalities,
therapies, medications, and follow-up.
3. What form of training will be required for patient
representative participants?
To integrate patient representatives effectively into the CPG
creation process, substantial preparatory training is needed
u
i
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One study observed that without preparatory training,
patient representatives feel that they are “participating
observers of technical language to which they could hardly
offer input.” Patient representatives contributed infrequently
to the discussions, had difficulty with the technical language,
only contributed during discussions of patient education,
and in general felt that their contributions were not subse-
quently acted on (5). Involvement of patient representatives
requires their understanding of the evidence. Difficulty with
medical terminology or other jargon is an important barrier
to active or meaningful involvement. Well-informed and
experienced patient representatives are more likely to have
meaningful exchanges with the GWC than those less
informed or less familiar with medical terminology (6). The
capacity for active participation in GWCs presupposes
foundations of access, knowledge, information, understand-
ing, confidence, agency, engagement, and advocacy (7).
Although resource intensive, it is feasible to train patient
representatives to understand the technical elements of
CPG development. It is not expected that these members of
GWCs understand most of the science related to specific
medical issues. They may also have limitations in their
ability to understand the details of SR or health economics.
Nonetheless, focused instruction in the CPG development
process will allow them to fulfill their role. Training is
required for understanding elements of recommendation
classifications and LOE, including treatment risks and
benefits, comparative efficacy, biostatistics, and clinical trial
design (i.e., the value of a single center case report or
retrospective observational data versus prospective blinded
RCT along with meta-analysis).
The Guideline International Network Patient and Public
Involvement Working Group has been created to support
the development, implementation, and evaluation of
guideline-oriented patient and public involvement pro-
grams. They have found that patient representative training
should cover the fundamentals of CPG development and
approaches for reporting back to patient constituencies.
Their participants concluded that training and support may
facilitate understanding of the technical aspects of CPG
development, address financial and organizational barriers
to participation, and enhance mutual understanding.
Guideline International Network Patient and Public In-
volvement Working Group collaboration priorities include
the development of recruitment methods, training and
support strategies, information material and tools, and
glossaries of technical terms used in CPGs (8).
The U.S. Cochrane Center and Consumers United for
Evidence-Based Medicine have created a web-based course,
“Understanding Evidence-based Healthcare: A Foundation
for Action,” through a grant from AHRQ (http://
us.cochrane.org/understanding-evidence-based-healthcare-
foundation-action) (9). This course is divided into 6 mod-
les: INTRO (what is evidence-based health care and why
s it important), ASK (importance of research questions inevidence-based health care), ALIGN (research design, bias,
and LOE), ACQUIRE (assessing harms and benefits),
APPRAISE (understanding healthcare statistics), and AP-
PLY (critical appraisal and making better decisions for
evidence-based care; determining causality) (9). The Co-
chrane Collaboration also has created the Cochrane Con-
sumer Network to engage patient representatives in the
development of SR, raise awareness among patient repre-
sentatives, that is, serve as a clearinghouse of patient
representatives for advisory groups, commission plain lan-
guage summaries, and recruit coauthors for reviews. New
ideas to promote patient representative involvement, such as
videos, workshops, learning materials, evaluations, and use
of social networks have been recently implemented.
4. Should the Task Force support the standard to have
CPGs publicly reviewed? How will that affect the final
product? How much of a burden will that put on
volunteers?
The IOM has recommended that public agencies, patients,
and representatives of the public should be external review-
ers. The IOM has also recommended that before publica-
tion, a draft of the CPG should be made available to the
general public for comment and reasonable notice of im-
pending publication should be provided to interested public
stakeholders. The IOM believes that for transparency,
fairness, completeness, and credibility, these recommenda-
tions are reasonable.
Currently, while the ACCF/AHA CPGs undergo an
extensive peer review process that includes scientific and
clinical content experts in addition to partnering, collabo-
rating, and other relevant professional societies, they are not
open to public review and comment. Fundamental to the
CPG development process is the ability to develop the CPG
without bias from commercial interests. The Workgroup
carefully considered the value provided by opening the draft
CPG to public opinion. It was recognized that a period of
open public comment would introduce a window for po-
tential interference in the process by industry and other
external stakeholders that cannot be adequately controlled
or managed. However, review of the CPG by public
representatives and stakeholders such as governmental
agencies, for example, the AHRQ and the U.S. Food and
Drug Administration (FDA), as well as scientific and
professional experts, is reasonable and recommended.
5. How will conflicts of interest (organizational, intel-
lectual, and practice based) be adjudicated by the
GWC and Task Force? What is an “intellectual
conflict” or “intellectual bias”?
The ACCF/AHA CPGs are in substantial compliance with
7 of the 8 standards for developing trustworthy CPGs
proposed by the IOM, (Workgroup 1 Comparison Table);
the CPG-SR intersection is the subject of the remainder of
this report. However, although the ACCF and AHA have
a rigorous policy for defining, disclosing, and managing
222 Jacobs et al. JACC Vol. 61, No. 2, 2013
ACCF/AHA Guideline Methodology Summit Report January 15, 2013:213–65RWI (4), the policy is currently undergoing evaluation and
updating for potential conflicts related to intellectual bias
and practice (or employment) bias.
Intellectual or clinical practice bias (the latter term is
operative when an individual‘s income is enhanced by
performing a certain test or procedure relevant to the
guideline topic) may result in a conflict of interest. An
intellectual or clinical practice bias is a predisposition of an
individual based on a reaction to a past or current event,
treatment, relationship, or other circumstance, or an opin-
ion, belief, or position so strongly held that it might prevent
the individual from exercising objective judgment about a
matter relevant to the work of the GWC. In the infrequent
scenario where, in the opinion of the Task Force or GWC
chair, a true bias (with its negative connotation) exists, that
individual will not be invited to participate as a member of
the GWC. In contrast, and similar to the ACCF/AHA
choice of the term RWI rather than COI related to industry,
the ACCF and AHA have chosen the terms intellectual
perspective and clinical practice perspective to denote intellec-
tual and practice-related opinions and expertise based on
evidence and/or experience. Both science and patient rep-
resentative GWCmembers with intellectual perspective and
clinical practice perspective must be identified and included
and their perspective disclosed and managed. It is under-
stood that they have an open-minded approach to evidence
and opinion that distinguishes them from individuals with
actual intellectual or practice bias.
Identification of Potential Intellectual or Clinical Practice
Perspectives of Candidates for Appointment to a GWC
Unlike potential conflicts arising from RWI, determination
of the existence of an intellectual or clinical practice per-
spective may be subjective and less readily apparent to the
Task Force. The key to mitigate effectively any conflict is
early identification and management of the conflict by the
Task Force initially and then by the GWC chair once the
work begins. The Task Force chair should be responsible for
implementing applicable intellectual and clinical practice
perspective procedures. Following are ways to identify and
adjudicate the perspectives:
1. Nominations to GWCs should be sought from trusted
organizations with a deep knowledge of the individuals
nominated. For example, both the ACCF and the AHA,
as well as many of their collaborating organizations, have
a thorough understanding of CPG development, and
each has a long relationship with numerous consumer
and scientific volunteers who would have the credentials
to serve on a GWC. From that relationship, each
organization has knowledge of individual volunteers’ life
experiences, professional work, and personal and profes-
sional views. It has been the practice of the Task Force to
maintain a balance of members with and without RWI
so that a minimum of 50% of the members have no
relevant RWI. In addition, the expertise of the GWCmembers is reviewed carefully to ensure that there is a
balance of perspectives. The ACCF and AHA could
request that other organizations meet these same
requirements. In addition, it is the practice of the
ACCF and AHA to provide additional scrutiny of
nominations by officers and senior staff before the
Task Force review. Seeking nominations from similar
organizations would reduce the likelihood of nomi-
nees with unknown perspectives.
2. Any candidate for GWC membership may be requested
to submit a detailed curriculum vitae, which the Task
Force and the GWC chair and staff can review for
possible intellectual or clinical practice perspectives (or
bias).
3. The GWC chair, at his or her discretion, should be
empowered to interview proposed GWC members who
are not well known or who have possible or unknown
intellectual or clinical practice perspectives.
4. Candidates for GWC membership may be asked to
complete a questionnaire through which they disclose
circumstances that might give rise to a potential or actual
perspective or bias related to the GWC assignment. The
questionnaire could include inquiries found in question-
naires typically used by charitable health organizations
with respect to director and officer perspectives or bias.
As some individuals may have difficulty recognizing or
disclosing their own intellectual or practice perspectives
that may lead to a conflict, questionnaire inquiries should
be broadly worded to obtain information from which the
GWC chair, Task Force, or staff could identify actual or
potential intellectual or practice perspectives.
5. At each meeting of the GWC, remind the members of
the policy whereby the group was formulated to incor-
porate a balance of RWI and varying intellectual and
clinical practice perspectives that we continue to manage
throughout the guideline writing effort.
6. Prospective GWC members should be educated about
being transparent with respect to their individual posi-
tion and be required to confirm that they will give
priority to ultimate patient health and well-being, quality
care, and value in their input and deliberation and when
voting on issues before the GWC.
Inclusion of Essential GWC Members With Known
Intellectual and Clinical Practice Perspectives
To develop the most effective CPGs, a GWC may require
the participation of an individual who is outspoken in
support of or against a particular procedure, medication, or
other matter relevant to the GWC’s work in the absence of
supportive data and therefore has a known intellectual or
clinical practice perspective. In such cases, the Task Force
should make certain that the GWC chair is informed of the
individual’s perspective and that the GWC membership is
balanced in viewpoint. All GWCs should be composed of
members determined to be able to apply fair judgment with
respect to all issues and particularly those in contention, so
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information relevant to the GWC task. In addition, the
GWC chair should make certain that the individual follows
the policy and procedures noted in the ACCF/AHA Meth-
odology Manual and Policies (4) as it applies to recusal from
discussion at the request of the chair.
Importance of Intellectual, in Comparison to Financial
Conflict and RWI, to External Organizations and
Government Regulators
Although conflicts arising from RWI have received most of
the attention by external groups, the Task Force should
effectively address all potential conflicts, whether arising
from RWI or intellectual or clinical practice perspective.
The Task Force should be prepared to demonstrate to
external groups that its policies for managing any conflict
are practical and effective.
Maintaining a Majority of GWC Members Without
RWI and a Balance of GWC Members With Intellectual
and Clinical Practice Perspectives Throughout the
Duration of CPG Development
All GWC members should be assessed by the Task Force
and GWC chair for potential relevant RWI at the outset of
the process. A majority of members who have no relevant
RWI must be assigned. They will be asked to commit to
developing no new RWI or other relationships that may
represent potential intellectual perspectives (e.g., serve as
principal investigator of a new study relevant to the CPG
topic) during the course of their service on the GWC. As
RWI or intellectual perspectives may arise in connection
with any one of the many recommendations a GWC may
make in developing a CPG, the GWC chair and staff
must be vigilant in identifying any relationships as they
arise and adjudicating them in accordance with estab-
lished policies.
1.2. Workgroup 1 Recommendations
1. At least 1 patient representative should be a full voting
member of the Task Force and each GWC. Patient
representatives could include patients, former patients,
members of patients’ families, caregivers, and laypeople
with “health literacy,” including scientists, statisticians,
engineers, and science writers.
2. All nonprofessional members of GWCs should avail
themselves of the U.S. Cochrane Center and Consumers
United for Evidence-Based Medicine’s “Understanding
Evidence-Based Healthcare: A Foundation for Action”
(9) or an equivalent online learning module before
accepting their position.
3. Patient representatives’ responsibilities should include
the formulation of key clinical questions, topic selection,
patient choices, values, and preferences, and issues sur-
rounding quality of life. They should be encouraged to
provide input about the selection of diagnostic tests and
treatment modalities.4. CPGs should be provided to an expanded group of
external reviewers before publication. External reviewers
would comprise a full spectrum of relevant stakeholders
(in addition to the current group of scientific and clinical
content experts, as well as to partnering, collaborating,
and other relevant professional societies), such as health-
care specialty societies, agencies (e.g., federal govern-
ment), and representatives of the public.
5. The ACCF/AHA CPG development policy should be
expanded to incorporate intellectual and clinical practice
perspectives. This information is discussed by the Task
Force during GWC formulation and the expertise of the
members is noted in the guideline section on writing
committee composition. This review and selection pro-
cess will be made transparent to the GWC during their
orientation meeting/teleconference, and GWC members
will be asked to verbally update the group if any changes
occur. For specific CPGs, consideration will be given to
capturing clinical practice perspectives on the author
RWI disclosure table if the GWC member’s income is
enhanced by performing a specific test or procedure that
is relevant to the guideline topic.
2. Workgroup 2: Standards for Initiating
a Systematic Review
See Workgroup 2 Comparison Table.
(Authors: Dr. Steven M. Ettinger, Chair; Drs. Donna K.
Arnett, Gregg C. Fonarow, Judith S. Hochman, Sharon-Lise
T. Normand, and Gordon F. Tomaselli)
SRs and the resulting evidence-based CPGs serve as
resources for healthcare decision-making policies. The
ideal guideline provides comprehensive protocols and
plans that are based on a thorough and extensive under-
standing of the medical literature, are scientifically valid,
and are void of clinical bias. The IOM defines 8
standards (Workgroup 2 Comparison Table), which
guide the creation of a focused SR policy, that are
essential for the creation of a scientifically valid CPG.
Workgroup 2 was charged with the task of reviewing
current ACCF/AHA standards for an SR and identifying
those elements that diverged from the recommendations
outlined by the IOM. Where applicable, the Workgroup
proposed alternative strategies relating to SR in an effort
to enhance current ACCF/AHA policies. The Work-
group acknowledged that one of the challenges posed by
modifications of existing ACCF/AHA evidence review
policies is related to the rapid expansion of medical
literature seen with publication of late-breaking clinical
trials and RCTs. The Workgroup expressed concern that
any modification in current ACCF/AHA evidence review
policy would result in significant delays in the creation of
evidence-based CPGs and the loss of clinical relevance of
the document. Recognizing that constraints relating to
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process, the Workgroup proposed 3 modifications of the
current ACCF/AHA evidence review policy. These mod-
ifications were developed based on a review of the
following key questions:
2.1. Workgroup 2 Questions for Consideration
1. Should other stakeholders/patient representatives be
involved in the development of the SR protocol? If
yes, to what level and what types of stakeholders/
consumers should be included (e.g., payers, policy
makers, patients, caregivers, family, and advocacy
groups)? What type of training would this group need
to be able to provide value to the current process?
Would the ACCF/AHA provide the training or out-
source it?
In an effort to expand the current ACCF/AHA process
related to the creation of CPGs (initially, with a focused
approach to a confined topic), 2 separate teams would be
created: an evidence review committee (ERC), tasked with
the SR process, and a GWC, tasked with creating the
scientific CPG. When appropriate, other stakeholders (e.g.,
policy makers and payers) would be invited to participate as
members of the ERC. The ERC will be responsible for all
phases of the SR process. By expanding the professional and
clinical expertise of the ERC, the “trustworthiness” of the final
document as well as its applicability to real-world decision
making may be enhanced (2). The Workgroup acknowledges
the added benefit of reviewing and incorporating unique data
sets provided by the “new” stakeholders that are potentially
outside the scope of current published scientific literature.
Although “unpublished data may not be used to support a
recommendation” (4), information collected by policy makers
and payers (e.g., economic and health plan data) may provide
additional insight into the effectiveness of healthcare recom-
mendations as it relates to various subpopulations (e.g., racial
and ethnic minorities, women, and the aged). Stakeholders
invited to participate in the ERC would undergo formal
training (by ACCF/AHA staff) related to understanding
current CPG writing policies of the ACCF/AHA. In addi-
tion, SRs require a rigorous scientific analysis of case reports,
case series, cohort studies, clinical trials, RCTs, and blinded
RCTs. An understanding of various point statistics (e.g.,
absolute risk difference, number needed to treat, number
needed to harm) and relative treatment effects (e.g., odds
ratio, relative risk, hazard ratio, and incidence rate ratio)
are essential components of the process. Individuals
invited to serve on the ERC may require additional
training related to methodology and statistical analysis
(or possess this expertise) with the expectation that this
would be made available by the ACCF/AHA.
2. Should we redefine how RWI and intellectual and
clinical practice perspectives are presently managed
for those involved in the development of the SR as itrelates to intellectual, professional, and personal as-
sociation? Would this make the process better?
The ACCF/AHA has an official RWI policy (4). The
definition of relevant is published in the first Appendix of
each CPG along with the authors’ relevant RWI. The
ACCF/AHA does not yet have an official policy regarding
intellectual and clinical practice perspectives (see Work-
group 1), although a balance of perspectives and opinions is
considered by the Task Force when selecting a GWC, each
author’s institution and title are provided in the document,
and a general statement about the expertise of the members
are noted under writing committee composition.
The following assumes that GWC structure will not
change, but when appropriate, a separate ERC will be
impaneled to draft and formalize a SR and include meth-
odologists and clinical content experts. Although the GWC
and ERC are separate committees, some members may be
selected to serve as liaison to both. As such, the ERC will
have the responsibility of developing the SR for use by the
GWC in generating the scientific clinical document. The
ERC will then review the developed CPG to confirm that
the recommendations are consistent with the findings of the
clinical trials and studies.
In general, we agree and are compliant with the IOM
recommendations on many aspects of RWI and intellectual
balance when constituting an SR team. The principle that
disclosure is necessary but may not be sufficient is impor-
tant. We also agree that individuals should be excluded if
their participation would diminish the public perception of
the independence and integrity of the newly created CPG.
The discussion around disclosure of conflict of interest/
RWI in the IOM report (Section 2.2.1) (2) included the
question of the structure of the ERC. We recommend that
the ERC include members completely free of RWI and
balanced with respect to intellectual and clinical practice
perspectives (as defined by Workgroup 1) but that the
GWCs adhere to the current ACCF/AHA policy of the
chairs and 50% of the committee being free of relevant
RWI. It is the consensus of the Workgroup that absence of
experts (perhaps with relevant RWI) on the GWC would
undermine the credibility of the review and CPG as much
or more than the presence of committee members with
RWI.
As stated by Workgroup 1, individuals thought to have
true bias would not be eligible to serve on a GWC. The
major issue pertains to the definition of intellectual and
clinical practice perspective and how this standard would be
adjudicated. It is unclear whether any method or protocol
for assessing intellectual and professional perspective can be
standardized and codified to allow for use across all
document-generating initiatives. We attempted to address
the various metrics that could be used to define intellectual
or professional perspective considering a number of possi-
bilities, including the percentage of one’s income or whether
income is enhanced if derived from a procedure, test, or
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ered under financial perspective); the publication and speak-
ing record of the candidate committee member on the topic;
and whether or not the home institution or practice would
benefit in a way that might promote a particular perspective,
among others (see Workgroup 1). However, regardless of
the metric(s) used, we recommend consideration of expand-
ing disclosure to include relevant professional/intellectual or
clinical practice perspectives in the published document for
selected guidelines.
We recognize that some of the changes outlined would
require an increase in the size and broadening of the
expertise of the groups constituted to develop CPGs.
Perhaps more importantly, the timeline for the entire
process most certainly will be lengthened. In this context,
the IOM report commented that an SR may take 1 year or
more to produce, so RWI and intellectual and practice
perspectives should be updated at regular intervals, but there
is no guidance as to what those intervals should be.
Currently, the ACCF/AHA process includes the provision
that GWC members avoid accepting new relevant RWI
throughout the duration of the development process.
3. Should the SR topics be formulated using the
PICO(TS) questions, AHRQ, or an alternative source?
Should we consider using a governmental agency, and
how would this affect the process (cost, time, and other
considerations)? How would we train physicians and/or
stakeholders/patient representatives?
In an effort to confirm the need for a focused update (or new
or revised CPG), summaries of late-breaking clinical trials
presented at major scientific conferences are compiled. The
goal is to identify evidence that is important to patient-care
issues (including but not limited to benefits relating to
quality of life, morbidity and mortality, and economic
outcomes). Members of the GWC and Task Force are
balloted as to whether the findings of the new study may
change a current recommendation. The Task Force reviews
the results and a decision is made as to whether a focused
update (or new or revised guideline) GWC should be
convened.
Once the decision is reached to create a new, revised, or
updated CPG, every effort is made to ensure the develop-
ment of an objective, transparent, and scientifically valid
document. The ACCF and AHA currently use a detailed
standard format to generate an evidence review for the
creation of CPGs (4). The ACCF, AHA, and IOM
acknowledge that creation of a CPG and formulation of
specific SR questions relating to the topic are challenging
processes. Standardized protocols may serve to streamline
and enhance the process by developing topic-specific ques-
tions that guide the direction of the SR (e.g., search for
studies, data extraction, synthesis, and presentation of find-
ings [2]). The IOM supports an SR that focuses on the
development of questions that deal with the “uncertainties
that underlie disagreement in practice and the outcomes andinterventions that are of interest to patients and clinicians”
(2). A CPG with newly developed recommendations cre-
ated in such a manner may find improved real-world
application and expand its value to healthcare decision
makers. The use of a PICO(TS) format (2) is recommended
by the Workgroup to develop evidence question(s) for the
SR of a CPG (initially, with a focused approach to a
confined topic). This effort will require additional resources
for the education and training of committee members.
Collaboration with other guideline developers and govern-
ment organizations should be explored.
4. Should we alter the current process of peer review as
it relates to the assessment of the SR protocol—
electronic registration, ACCF/AHA Web sites— or
continue the current process of an internal review by
the GWC?
As stated previously, SR and resulting evidence-based
CPGs serve as a resource for healthcare decision-making
policies. The IOM suggests that a formal review process be
created to publicly vet the SR as early as possible in the
process. The benefits of this recommendation include min-
imizing bias, providing an opportunity to identify ongoing
SR by other groups, thereby avoiding unnecessary (dupli-
cate) efforts, and encouraging collaboration among various
organizations (2). Given these potential benefits, the Work-
group acknowledges that a formal peer review process of the
SR may enhance the clinical value of the final document. It
is essential that these SRs be rigorous, credible, and, to the
extent possible, free of commercial, professional, and intel-
lectual bias. Unlike the ACCF/AHA, the IOM does not
distinguish between intellectual bias and perspective.
Rather, the IOM defines certain standards, which are
designed to minimize bias, that guide the creation of a
focused SR policy. These include a defined protocol that
ensures balanced and unbiased user and stakeholder input to
the SR before the initiation of the process and a well-
defined policy to manage bias and RWI for all individuals
involved in the SR.
Having a mechanism for various stakeholders, including
the public, payers, and governmental agencies, to be able to
provide input on which topics would benefit from an SR,
how the review is designed and conducted, and potential
data sources is important. The Workgroup supports the
recommendation that the SR questions be vetted by agen-
cies in the public realm (e.g., FDA, Centers for Medicare
and Medicaid Services, health plans such as Kaiser Perma-
nente, and United Healthcare). ERC and GWC members
would be responsible for determining the scientific validity
of the comments, if there would be a need to modify the
PICO(TS) question(s), and whether additional data/studies
should be included in the SR. Concerns relating to the
number of comments and potential bias of the public
reviewers may be problematic, and therefore no direct
response would be anticipated or required by the ERC and
GWC. With the creation of an ERC and the inclusion of
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formal peer review and SR process would be enhanced. It is
recommended that members of the ERC be responsible and
make final decisions about the design, analysis, and report-
ing of the identified and selected data.
2.2. Workgroup 2 Recommendations
1. An ERC composed of content experts, methodologists,
statisticians, and other identified stakeholders (policy
makers and payers) should participate in the creation of
ACCF/AHA CPGs (initially, with a focused approach
to a confined topic). The ERC should interact with the
members of the GWC; however, the ERC’s responsibil-
ities will be separate, distinct, independent, and clearly
delineated.
2. In an effort to standardize the process by which ACCF/
AHA CPGs are created, the PICO(TS) format should
be applied to develop the SR questions. It will be the
responsibility of the ERC to create the format of the SR.
3. The current peer review process of ACCF/AHA CPGs
should be expanded to include a formal peer assessment
of the SR protocol. External stakeholders and patient
representatives should be included in this expanded
process that will serve to enhance the applicability of the
document to real-world decision-making policies and
clinical scenarios.
3. Workgroup 3: Standards for Finding and
Assessing Individual Studies
See Workgroup 3 Comparison Table.
(Authors: Dr. Robert A. Guyton, Chair; Drs. Jonathan L.
Halperin, Sidney C. Smith, Jr., and Marnie Bertolet, and Ms.
Marguerite A. Koster)
The 2 publications from the IOM released in 2011, “Clin-
ical Practice Guidelines We Can Trust” (1) and “Standards
for Systematic Reviews” (2), present a challenge to devel-
opers of CPGs. A compelling argument is made that CPGs
are currently not at the level that we seek as we allocate
scarce societal resources to fund an expanding repertoire of
sophisticated preventive measures and therapies for human
illness. In particular, the authors of “Clinical Practice
Guidelines We Can Trust” stated that quality healthcare
practice is guided by the combination of critically appraised
and synthesized scientific evidence, clinical experiential
knowledge and skill, and patient values and preferences (1).
In this context, a new definition of CPGs has been created:
CPGs are statements that include recommendations intended to
optimize patient care that are informed by an SR of evidence
and an assessment of the benefits and harms of alternative care
options (1).
Relevant to the issue of finding and assessing individual
studies, Standard 4.1 states that developers of CPGs should
use SRs that meet the standards set by the IOM Committeeon Standards for Systematic Reviews of Comparative Ef-
fectiveness Research (2). In addition, Standard 5.1 states
explicitly that a summary of available evidence (and eviden-
tiary gaps) and a description of the quality of evidence
(including applicability), quantity (including completeness),
and consistency of the aggregate available evidence should
be a part of the CPG process, including a rating of the level
of confidence in the evidence supporting the recommenda-
tion (1).
The charge to this Workgroup is also highlighted in the
criteria for inclusion of CPGs in the National Guideline
Clearinghouse. These criteria state that corroborating doc-
umentation must be available to prove that a systematic
literature search of existing scientific evidence from peer-
reviewed journals was performed during the CPG develop-
ment process. It is notable that CPGs are not excluded from
the National Guideline Clearinghouse if gaps in scientific
evidence for some recommendations are present and there is
documentation that a search has been made for this evi-
dence and the gaps are specified in detail. The IOM report
also states that (guidelines) that have not included a thor-
ough SR of the relevant scientific evidence should be
excluded from the National Guideline Clearinghouse (1).
Challenges in Finding and Assessing Individual Studies
The area of evidence appraisal is described in the IOM report
as “besieged with problems.” However, there is a consensus
that a standardized rating of evidence quality facilitates the
application of individual studies to the risk-benefit analysis that
is the foundation of a clinical recommendation.
There are major concerns about bias and relevance of
published studies. A 2005 study of trials published in the
New England Journal of Medicine, the Journal of the American
Medical Association, and The Lancet found that approxi-
mately three fourths of the trials were funded by industry
(1). Another study revealed that high-quality commercial
trials in this study were found to be 5.3 times more likely to
endorse the product of the funding industry than noncom-
mercially funded studies of the same product (1). This is
certainly understandable, as many of these trials constitute
preapproval research conducted for approval or labeling of
either devices or medications. The trials have been designed
to prove that the drug or device is safe and effective. These
trials often tend to utilize young healthy patients who differ
from the actual target population of the drug or device. The
trials may intentionally use as a comparator a placebo rather
than a competitor drug, and often surrogate endpoints are
used to allow a shorter period of time for follow-up.
Even when studies have minimal bias (i.e., they have high
internal validity), they may not be relevant for the patient
population being considered by the GWC. This is referred
to as relevance, generalizability, or external validity. RCTs
often have an underrepresentation of older patients, of
patients with comorbidities, of ethnic minorities, and of
low-income patients. The IOM report quoted a 2007 study
of evidence quality in cardiovascular risk management and
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on high-quality evidence. The most common reason for
downgrading the quality of evidence in RCTs was concern
about generalizability, that is, extrapolating from the care-
fully selected trial enrollees to the general population in
question (1).
The IOM report “Standards for Systematic Reviews”
offered a set of standards for conducting the SR and
elements of performance within these standards (2). In the
area of finding and assessing individual studies, 6 standards
were offered, composed of 30 elements that are addressed
specifically in the Workgroup 3 Comparison Table. The
Workgroup quickly recognized a number of challenges.
First, ACCF/AHA CPGs have been focused on clinical
topics rather than specific clinical questions. The standards
for SR in general expect the SR to be focused around a
limited number of clinical questions that may be optimally
organized around the PICO(TS) format.
The second challenge the Workgroup faced was the
labor-intensive and resource-intensive nature of SR. In the
past, ACCF/AHA CPGs have used literature databases
with search engines and relevant topics, key words, or
medical subject headings. This has been augmented by the
extensive knowledge of the literature derived from the
experience of the GWC. The primary potential problem
with the current system is the possibility of bias, in partic-
ular, the perpetuation of bias from year to year and from
guideline to guideline.
The third challenge discussed by the Workgroup was the
difficulty in transitioning from the current CPG process to
a process focused around SR of relevant clinical questions.
An effort was made to find an iterative transition from the
current process to a process more fully and carefully in-
formed by SR with implementation of multiple elements of
performance from the IOM report.
3.1. Workgroup 3 Recommendations
IOM Standard 3.1: Conduct a comprehensive,
systematic search for evidence
A formal SR of the evidence for the entire scope of topics in
an ACCF/AHA CPG may not be feasible given existing
resources. The Workgroup believes that a more formal
review of the literature for ACCF/AHA CPGs, incorpo-
rating many of the performance elements proposed by the
IOM committee, is an appropriate and necessary step for
our guidelines to remain a trustworthy source for recom-
mendations in cardiovascular clinical practice. If a compre-
hensive SR is not feasible, the processes and procedures used
to review the evidence need to be predetermined and
documented by an ERC that works with the GWC but is
functionally separate.
The Workgroup believes that all evidence reviews should
be conducted by staff research specialists who have had
training in developing comprehensive search strategies and
conducting searches.The Workgroup believes that the ACCF/AHA CPG
process needs to move in iterative manner toward a more
robust SR of the literature. Acknowledging that a complete
formal SR for all CPG topics is not possible at this time,
given existing resources, the Workgroup recommends that 2
or 3 key clinical questions within selected upcoming CPGs
be used to pilot an SR process. These key clinical questions
could be part of a focused update or a focused approach to
a confined topic. It should be noted, however, that if a
focused update is to be the pilot of an SR, then the
appropriate PICO(TS) question would need to be formu-
lated for the focused update, and all relevant evidence, not
just new evidence, would need to be reviewed. A “focused”
update does not imply a limited SR. It does imply that the
update question might be adequately framed in a single
PICO(TS) question for efficient SR.
IOM Standard 3.2: Take action to address potentially
biased reporting of research results
Gray literature databases should be searched and relevant
findings included as appropriate as evidence in the SR. Gray
literature sources would include clinical trial registries (e.g.,
http://www.clinicaltrials.gov), clinical databases such as the
National Cardiovascular Data Registry or the Society of
Thoracic Surgery database, industry reports to the FDA,
and unpublished abstracts 2 years old. Lack of complete
information and lack of peer review are issues that need to
be considered with the gray literature. The gray literature
should be searched especially for signals of unreported safety
issues.
Communication with researchers about information to
assess the risk of bias in a study is appropriate, as is
communication about unpublished data that may supple-
ment the published data of a study. Again, the absence of
peer review is a particularly prominent issue, as is the
potential perpetuation and exaggeration of the bias of the
sponsor and/or researcher.
IOM Standard 3.3: Screen and select studies
For each pilot SR, criteria should be prespecified for
inclusion or exclusion of studies. The use of clinical ques-
tions in a PICO(TS) format would greatly facilitate this
process. Observational studies in addition to RCTs should
be included. A separate ERC should conduct an SR of the
literature. Members of the ERC should be without RWI
relevant to the topic of the SR. The Workgroup recom-
mends training a cadre of volunteer members to conduct the
SR, including screening and selecting studies, abstracting
data from the studies, and assessing the quality of the
studies. ACCF/AHA members early in their academic
careers may find benefit in becoming involved in this process
with no financial remuneration. Academic credit might
include letters to department chairs, listing as part of a
group that conducts SR, and listing of ERC members as
coauthors of the CPG along with the GWC. Individuals
who screen and select studies would need to work from
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and verification of accuracy and consistency. The ACCF/
AHA research staff should perform the literature searches.
The titles and abstracts of all articles should be reviewed
with dual screening by 2 ERC members, with a third
member adjudicating conflicts. In addition to RCTs, obser-
vational studies should be included to address gaps in
evidence from RCTs. Staff and screeners should also look
for observational studies and unpublished studies seeking
benefits and potential harm that would otherwise be missed
if only RCTs were reviewed.
IOM Standard 3.4: Document research
The current ACCF/AHA CPG methodology is compliant
with this IOM standard with the exception of documenta-
tion of the reason for exclusion of peer-reviewed RCTs and
large observational trials published in major journals. This
exclusion judgment should be documented and justified for
each such study.
IOM Standard 3.5: Manage data collection
For each pilot SR, a standardized data extraction form
should be developed that includes some standard elements
and additional elements unique to the PICO(TS) question
under consideration. The data extraction form should be
piloted in a few studies and then revised. For the broader
clinical questions in the more expansive CPGs (the portions
of the guideline not subject to a formal SR), a similar data
extraction form should be developed.
IOM Standard 3.6: Critically appraise each study
Documentation of the assessment of 1) the risk of bias, 2)
the relevance of the study’s populations, interventions, and
outcomes measures, and 3) the fidelity of implementation of
interventions is essential. The system used to assess the
studies in these 3 domains is controversial. Multiple scoring
tools exist, including the one under evaluation by the
ACCF/AHA.
The Cochrane Risk of Bias tool uses a qualitative,
domain-based evaluation and judges each study across 6
domains of bias: selection, performance, detection, attrition,
reporting, and “other.” In each domain, bias is judged as low
risk of bias, high risk of bias, or unclear risk of bias, with
brief supporting comments for each judgment. There also is
a summary judgment for each study summarizing the overall
risk of bias incorporating information from all 6 domains. It
is recommended that the summary judgment be outcome
specific (10). The Cochrane tool is a nonquantitative tool of
the type thought by many (including members of the Work-
group) to be preferable to quantitative tools or checklists.
For each study, the same 3 members of the ERC who
performed data extraction could simultaneously perform a
quality assessment (2 members perform a quality assessment
with the third member to adjudicate differences). Whether a
scoring tool is used or a nonquantitative tool such as the
Cochrane tool is used, a separate tool is needed for observa-tional studies and registries that is distinct from the tool used
for RCTs.
Proposal for the Critical Assessment of Each Study
The critical appraisal of each study has 3 required elements
of performance:
1. Systematic assessment of the risk of bias, using pre-
defined criteria
2. Assessment of the relevance of the study’s populations,
interventions, and outcomes measures
3. Assessment of the fidelity of the implementation of the
interventions
The Workgroup proposes the following system for critical
appraisal of each study:
1. This system will be used in the pilot SR, conducted in
conjunction with CPGs. In this case, it is anticipated
that the assessment of the quality of the study will be
focused within the context of a PICO(TS) question.
2. It is expected that a 3-member team from the ERC
associated with the GWC will conduct the critical
assessment of each study. For efficiency, it is suggested
that these 3 people be the same 3 people who conduct
the data extraction from each selected study.
3. The pilot system for critical appraisal of each study will
be composed of a quantitative assessment, a yes/no
assessment of key features of the studies, and a scoring
of each of the 3 domains identified by the IOM: risk of
bias, relevance, and fidelity of implementation.
4. A quantitative assessment is currently undergoing eval-
uation and validation by the Task Force. This quanti-
tative assessment will need some revision for application
to observational studies and for focused assessment of
the 3 domains identified by the IOM.
5. The qualitative assessment of the key features of each
study may be the yes/no answers on the quantitative
assessment.
6. A scoring of the quality of the study in each of the 3
domains will be qualitatively accomplished judgmental
scoring by the 3 members of the ERC. The domain
“risk of bias” should be renamed “freedom from bias”
(or “internal validity”) so that the judgment system is
directionally similar for all 3 domains. Otherwise, a
high-quality assessment of the “risk of bias” domain
would be “low,” while such an assessment of relevance
or fidelity would be “high.” By renaming “risk of bias”
as “freedom from bias,” all 3 domains can have similar
scoring of high to low, indicating high to low quality in
that domain. For each of the 3 domains—1) freedom
from bias, 2) relevance, and 3) fidelity of implementa-
tion—one of the following judgments will be assigned:
fatally flawed, low (low freedom from bias, low rele-
vance, or low fidelity), intermediate, or high. In addi-
tion, there will be a summary assessment of each study:
fatally flawed study, low-quality study, intermediate-
quality study, and high-quality study.
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what independent of the PICO(TS) question being
addressed, the other 2 domains, relevance and fidelity of
implementation, are necessarily dependent on the pop-
ulation, intervention, comparator, outcome, and setting
under consideration. Therefore, the assessment of the
quality of the study must be made in the context of the
PICO(TS) question under consideration.
8. For other studies being considered in other parts of the
CPG, a similar evaluation of the quality of the individ-
ual studies may be carried out. It will be necessary,
however, to clearly identify, for each proposed recom-
mendation, the population under consideration, inter-
vention, comparator, outcome and setting, at least in a
broad and general way.
9. With this system, each study, when considered as
part of the body of evidence for assessment of the
LOE for a specific recommendation, will have an
overall quality assessment. Each study will also have
a qualitative assessment of quality in each of the 3
domains: freedom from bias, relevance, and fidelity
of implementation. The scoring tool, if a quantitative
tool is used, and the yes/no answers on key elements
of the study will be used to inform the judgment on
the 3 domains and the summary judgment of the
quality of the study.
10. It is suggested that the proposed system might
combine the advantages of the quantitative tool, the
qualitative yes/no assessment of key points in the
study, and the need for judgment, which is study
specific and context specific in the assessment of
quality in each of the 3 domains and the summary
study quality assessment.
4. Workgroup 4: Standards for Synthesizing
the Body of Evidence
See Workgroup 4 Comparison Table.
(Authors: Dr. Jeffrey L. Anderson, Chair; Drs. Nancy M. Albert,
Elliott M. Antman, David L. DeMets, Eduardo Ortiz, Eric D.
Peterson, and Clyde W. Yancy, and Ms. Marguerite A. Koster)
Workgroup 4 was assigned 2 overarching tasks: 1) to
address setting standards for synthesizing a body of evidence,
and 2) to review and make recommendations on grading of
guidelines, that is, on the ACCF/AHA system of establish-
ing COR/LOE.
The first task was subdivided into 4 sections, following
the IOM’s report on “Standards for Systematic Reviews.”
These 4 sections comprised the following standards:
1) assessing the quality of a body of evidence, 2) describing the
quality of a body of evidence, 3) qualitative synthesis of a
body of evidence, and 4) quantitative assessment of a body of
evidence (e.g., meta-analysis of the universe of studies to
address a specific research question) and how to determinethe need for qualitative and/or quantitative evaluations. It
was suggested that the formulation of specific research
questions be guided by the mnemonic PICO(TS).
Workgroup 4’s scope of work and charge included the
important task of comparing and contrasting the IOM
report with ACCF/AHA CPG methodology for synthesiz-
ing the body of evidence, which is summarized in the
Workgroup 4 Comparison Table. Where differences or
deficiencies in current ACCF/AHA CPG processes were
identified, theWorkgroup was to propose recommendations
for bringing these into compliance with the IOM recom-
mendations or to defend the current processes where the
Workgroup thought a change was not warranted.
Three key areas of discussion emerged with respect to the
differences between the IOM recommendations and the
ACCF/AHA processes: 1) what was the strength of evi-
dence backing the advantage to patient care (superiority)
of the IOM proposal? 2) what resources/cost implications
would be associated with the proposed change (an over-
lapping concern)? and 3) how disruptive would a major
change be to current ACCF/AHA programs (caused by a
domino effect throughout the 2 organizations and the
cardiovascular universe) from the current CPG COR/
LOE grading system?
Overall, the Workgroup thought that the current ACCF/
AHA CPG methodology has served the cardiovascular
community well, as evidenced by improved outcomes asso-
ciated with adherence to CPG recommendations (11,12).
Thus, the Workgroup endorsed a plan of incremental
change occurring over time, that is, “evolution rather than
revolution,” assessing the impact and value of change at each
step along the way.
4.1. Workgroup 4 Questions for Consideration
1. Qualitative synthesis of a body of evidence: assessing
and describing the quality of a body of evidence.
Qualitative synthesis deals with analyzing the essen-
tial characteristics of a study, that is, risk of bias,
consistency, precision, and directness; and, for obser-
vational studies, additionally dose-response associa-
tion, confounding factors that would change the
observed effect, and strength of association. Ques-
tions posed to the Workgroup included the following:
• How does the current ACCF/AHAmethodology look
at the qualitative characteristics of a study and then
look at the main variables across a body of evidence?
• How do other evidence grading methodologies (i.e.,
Grading of Recommendations Assessment, Develop-
ment and Evaluation [GRADE], NHLBI) address the
synthesis and analysis of characteristics across a body
of evidence? What is required for such an analysis, for
example, data summary tables?
• How does the qualitative synthesis/analysis change
when some of the studies are observational?
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important for RCTs as well as observational studies?
• What is the optimal and most practical/efficient way to
synthesize evidence looking across all studies and to
focus on trends, themes, relevance, and observations?
Because Workgroup 3 addressed assessment of quality at
the individual study level, Workgroup 4’s recommendations
apply to assessment of evidence quality across the body of
evidence.
The term qualitative synthesis refers to evaluating and
summarizing the findings of a body of evidence for each
prespecified outcome of interest in a specific clinical ques-
tion. The IOM further elaborates on the definition of
qualitative synthesis as
. . . an assessment of the body of evidence that goes beyond
factual descriptions or tables that, for example, simply detail
how many studies were assessed, the reasons for excluding
other studies, the range of study sizes and treatments
compared, or quality scores of each study as measured by a risk
of bias tool. While an accurate description of the body of
evidence is essential, it is not sufficient (2, p. 196).
The IOM report recommends 4 elements of performance
for conducting a qualitative synthesis of a body of evidence
for an outcome of interest:
1. Describe the clinical and methodological characteristics
of the included studies, such as their size, inclusion or
exclusion of important subgroups, timeliness, and other
relevant factors.
2. Describe the strengths and limitations of individual
studies and patterns across studies in plain terms, how
flaws in the design or execution of the study (or groups
of studies) could bias the results, explaining the reason-
ing behind these judgments.
3. Describe the relationships between the characteristics of
the individual studies and their reported findings and
patterns across studies.
4. Discuss the relevance of individual studies to the popu-
lations, comparisons, cointerventions, settings, and out-
comes or measures of interest.
The IOM report described 8 “basic characteristics of qual-
ity” that are essential for assessing the quality of a body of
evidence for a particular outcome of interest, and a discus-
sion of these characteristics is an important component of
the qualitative synthesis. Characteristics are risk of bias
(limitations in study design and conduct); consistency of
results across studies; precision of the estimates of effect;
directness of the evidence in terms of study design, popu-
lations, interventions, comparisons, or outcomes; and re-
porting bias. For observational studies, additional charac-
teristics include dose-response association, plausible
confounding factors that would change an observed effect,
and strength of association (i.e., large magnitude of effect).
Initially developed by the GRADE Working Group (13),these characteristics for assessment of a body of evidence
have been endorsed by the Cochrane Collaboration, the
AHRQ Effective Health Care Program, and many medical
professional societies and healthcare organizations involved
in evidence review efforts, especially for development of
CPGs.
The GRADE system (13) designates 4 levels for assess-
ing the overall quality of a body of evidence: “high,”
“moderate,” “low,” and “very low.” These levels refer to the
degree of confidence in the estimate of effect. A body of
evidence consisting of RCTs begins at the highest level and
can be downgraded on a point system based on method-
ological limitations of the studies (risk of bias), indirectness
of evidence, inconsistency of reported results, imprecision of
the effect estimates, and/or publication bias. A body of
evidence consisting of observational studies begins at a “low”
level and can be upgraded based on a large magnitude of
effect, a dose-response association, or few confounding
factors that would change the reported effect. The GRADE
Working Group has developed a software program,
GRADEprofiler (“GRADEpro”), for conducting the qual-
ity assessment of a body of evidence (14). The software
generates 2 types of tables that are useful for summarizing
the quality assessment: “evidence profile” tables and a
“summary of findings” table.
The AHRQ Effective Health Care program (15) has
essentially adopted the GRADE framework; however, it
uses the term “strength” to assess what GRADE calls the
“quality” of a body of evidence. Rather than use the term
“very low” to categorize the lowest quality of evidence, the
Effective Health Care program uses the term “insufficient.”
Furthermore, the Effective Health Care program has an
additional domain to assess “applicability” of the body of
evidence to account for the degree to which the evidence
is relevant to patient populations, settings, diseases or
conditions, interventions, comparators, and outcomes of
interest. At this time the Effective Health Care program
does not mandate use of GRADEpro or other software
and allows for use of other weighting systems or a
qualitative approach.
Many medical professional societies (e.g., American Col-
lege of Physicians, American College of Chest Physicians,
and the American Academy of Neurology), government
organizations (e.g., the NHLBI), and healthcare organiza-
tions (e.g., Kaiser and the Institute for Clinical Systems
Improvement) have revised their grading systems and qual-
itative syntheses of a body of evidence to incorporate all or
some of the characteristics or domains used by GRADE,
AHRQ, the Cochrane Collaboration, and other leaders in
SR methodology. Some organizations use a combination of
the GRADEpro software evidence profiles and summary of
findings tables and additional narrative description to char-
acterize the body of evidence, whereas others rely on an
entirely descriptive approach.
Most ACCF/AHA CPGs currently include narrative
descriptions and evidence tables detailing the clinical char-
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inclusion/exclusion criteria, endpoints, point estimates, and
confidence intervals). Current ACCF/AHA CPGs do not,
however, explicitly evaluate a body of evidence by outcome,
nor do they explicitly take into consideration an evaluation
of the basic characteristics of quality using a specific check-
list or quality scale tool. Rather, the assessment of quality
(and strengths and weaknesses of each study) is inherent to
the overall evidence review and is based on the recognized
expertise of the GWC.
4.2. Workgroup 4 Recommendations for Assessing
and Addressing the Quality of a Body of Evidence
1. Accept the IOM-recommended basic characteristics of
quality and elements for assessing quality across studies.
2. Standardize the method of assessment and description of
the quality of the body of evidence across studies and
carry out a qualitative assessment of individual studies
and aggregated studies. (This will require allocation of
resources for additional methodological expertise, be-
cause this exercise is judged to be beyond the expertise
and time commitment expected of GWC members
alone; an ERC would likely assume this role.)
3. Depict qualitative assessment across studies addressing
the key elements for each PICO(TS) question in a
summary table (e.g., similar to GRADE or other formats
Table 4.1. Example of GRADE Depiction of Evidence Profile Ac
GRADE Evidence Profile: Antibiotics for Children With Acute Otitis Media
Quality Assessment
No. of studies
(Design) Limitations Inconsistency Indirectness Imprecision
Pu
ain at 24h
(RCT) No serious
limitations
No serious
inconsistency
No serious
indirectness
No serious
imprecision
Un
ain at 2–7 d
0 (RCT) No serious
limitations
No serious
inconsistency
No serious
indirectness
No serious
imprecision
Un
earing, inferred from the surrogate outcome abnormal tympanometry—1 mo
(RCT) No serious
limitations
No serious
inconsistency
Serious
indirectness
(because of
indirectness of
outcome)
No serious
imprecision
Un
earing, inferred from the surrogate outcome abnormal tympanometry—3 mo
(RCT) No serious
limitations
No serious
inconsistency
Serious
indirectness
(because of
indirectness of
outcome)
No serious
imprecision
Un
omiting, diarrhea, or rash
(RCT) No serious
limitations
Serious
inconsistency
(because of
inconsistency
in absolute
effects)
No serious
indirectness
No serious
imprecision
Un
CI indicates confidence interval; GRADE, Grading of Recommendations Assessment, Developme
Reproduced from Guyatt et al. (16).[Table 4.1]).4. Where appropriate, provide a risk-of-bias assessment
table across studies (e.g., similar to the Cochrane format
(10) that includes items such as random sequence gen-
erator, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incom-
plete outcome data, selection report, or other bias.
5. Generate standardized summary and evidence table tem-
plates specific to ACCF/AHA requirements.
6. When available, high-quality SRs from reputable orga-
nizations (e.g., the Cochrane Collaboration and AHRQ
evidence-based practice centers [EPC]) should be used.
If a new SR is needed, resources will need to be secured
to pursue de novo analyses.
7. Notwithstanding these efforts to standardize and im-
prove the qualitative analysis of bodies of evidence, every
effort should be made to minimize delays in time for
CPG development/revision.
2. Standards for quantitative analysis (i.e., meta-analysis):
Quantitative analysis refers to conducting a (multiple)
meta-analysis and deals with the statistical manipulation
of data along with the aggregation of data presented in
individual studies. This analysis should address hetero-
geneity among study effects, determine the statistical
uncertainty for all estimates, and assess the sensitivity of
analysis based on the changes/differences in protocol,
Studies
Summary of Findings
Number of Patients Absolute Risk
on
Placebo Antibiotics
Relative Risk
(95% CI)
Control
Riska
Risk Difference
(95% CI) Quality
ed 241/605 223/624 RR 0.9
(0.78–1.04)
367/1,000 Not Significant High
ed 303/1,366 228/1,425 RR 0.72
(0.62–0.83)
257/1,000 72 fewer per
1,000 (44–98)
High
ed 168/460 153/467 RR 0.89
(0.75–1.07)
350/1,000 Not Significant Moderate
ed 96/398 96/410 RR 0.97
(0.76–1.24)
234/1,000 Not Significant Moderate
ed 83/711 110/690 RR 1.38
(1.09–1.76)
113/1,000 43 more per
1,000 (10–86)
Moderate
Evaluation; RCT, randomized controlled trial; and RR, risk ratio.ross
blicati
Bias
detect
detect
detect
detect
detectassumptions, and study selection.
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The standard evidence review to date has focused on
qualitative attributes of relevant data to determine the LOE
that might inform a CPG. This approach, although very
pragmatic and reasonably successful in the past, involves
subjective assessments and may be less appropriate for
increasingly complex data in contemporary clinical trials
and/or observational data.
Addressing Conventional Quantitative Analyses
Broadly speaking, a quantitative analysis would consider a
more detailed assessment of the strength of evidence beyond
the ordinary “positive” RCT. The notion of a positive trial
as the ultimate arbitrator of an evidence base does not speak
to the magnitude of the evidence or the potential impact of
the evidence if applied to de novo patient cohorts. Specifi-
cally, a threshold p value of 0.05 is known to be an arbitrary
threshold to determine significance and practically can be
defined as the likelihood that the given finding is a random
occurrence in 5%, or 1 chance in 20. This may or may not
be compelling for certain interventions, and a stronger
threshold, p0.01, or the randomness is 1 chance in 100,
may be more appropriate. This may be especially the case for
more invasive or expensive interventions. An even more
stringent threshold might be appropriate for large observa-
tional datasets that have a large number of observations, and
a p value of 0.05 might be easily reached for nonsensical
(nonclinically significant) observations. In these cases, a
threshold of p0.001, or 1 chance in 1,000 that the
results are due to random accident, might be the preferred
strategy. Thus, a more appropriate fit of statistical threshold
with a data source and within the context of the given data
might be a more reasonable approach and would add a
helpful quantitative analysis to the current ACCF/AHA
evidence review. It is likely that current GWCs exercise this
kind of thoughtful review empirically, but as a policy
statement, direction for these types of quantitative assess-
ment have not previously existed.
Considering Newer Quantitative Analyses
Beyond the determination of p values, additional quantita-
tive insight is determined from a review of confidence levels.
Understanding the “splay” of data may put the top line
findings of a given study in a different context and either
strengthen the LOE despite a modest level of statistical
significance or temper the LOE for a reasonable level of
significance but with broad confidence levels. Similarly,
evaluating relative risk reduction versus absolute risk reduc-
tion can be quite informative. A large multithousand-
patient study with a relative risk reduction of 0.15 might
reflect an actual risk reduction of only 1% or 2%. This is
important information that generates a new perspective/
interpretation of clinical trial results. The number needed to
treat versus the number needed to harm represents a very
informative quantitative representation of available dataand further allows discrimination of the veracity of the
findings. Importantly, the comparison of number needed
to treat and number needed to harm captures the burden
of risk associated with emerging new therapies for car-
diovascular disease.
Incorporating More Rigorous Quantitative Methodology
Meta-analyses and Bayesian analyses are powerful data
analytical tools that may further inform the significance of
candidate data to support the generation of CPGs. How-
ever, care must be exercised in the use of both of these
rigorous methodologies. Meta-analyses are subject to the
quality of the studies that are aggregated to either identify a
stronger signal of benefit or harm. Publication bias is a
consistent concern, and a funnel plot analysis is necessary to
mitigate this known source of bias. Moreover, many trials
are sufficiently dissimilar so that the construct of a meta-
analysis may be fundamentally flawed at the outset. How-
ever, a well-constituted meta-analysis may confirm findings
from isolated trials and can be of sufficient quality to inform
CPGs at the highest tier of evidence.
Bayesian analyses are similarly not perfect tools. The
prior probability of an event determined from clinical
judgment sets the threshold from which the posterior
probability of a Bayesian analysis might be constructed. Bias
may influence even a Bayesian analysis. However, a Bayes-
ian approach is the closest statistical analytic model that
approximates clinical judgment and decision making; in
clinical practice, all practitioners begin with a “prior prob-
ability,” that is, an informed perspective of the expected
clinical response to or outcomes of a test or intervention.
Thus, the results of a well-performed Bayesian analysis may
be very helpful in the construct of a CPG.
A more contemporary evidence review is needed for novel
datasets that include not only traditional RCTs but also
large observational datasets, adaptive clinical trial designs,
genomic datasets, and nonrandomized data. As more quan-
titative data standards are adopted, it will be necessary to
have statistical expertise embedded in the infrastructure of
all CPG generation paradigms.
4.3. Workgroup 4 Recommendations for Standards
for Quantitative Analysis (i.e., Meta-Analysis)
Across a Body of Evidence
1. GWCs, in conjunction with the Task Force, should
determine when a specific meta-analysis is needed.
2. With statistical consultation, preferred acceptable meth-
ods for meta-analysis (including a Bayesian analysis
when appropriate) should be defined in each instance.
3. When available, high-quality meta-analyses from repu-
table organizations (e.g., the Cochrane Collaboration
and AHRQ EPC) should be used. If a new meta-
analysis is needed, resources will need to be secured to
pursue de novo analyses.
4. Notwithstanding efforts to standardize and improve the
approach to quantitative analyses across studies, every
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CPG development/revision.
. Review of ACCF/AHA COR/LOE versus other
grading methodologies such as GRADE and NHLBI
methodology for grading evidence and recommenda-
tions. Questions posed to the Workgroup on grading
recommendations included the following:
• What features of the COR/LOE allow for the syn-
thesis and grading of evidence across multiple studies?
• What features of GRADE, AHRQ EPC, and
NHLBI methodology allow for the synthesis and
grading of evidence across multiple studies?
• What are some changes that may help the COR/
LOE incorporate/improve on its current methods of
synthesizing and grading evidence across multiple
studies?
The objective of this question was to take a “10,000-foot”
iew of the ACCF/AHA COR/LOE approach and how
his current methodology addresses and/or allows for the
verall synthesis of evidence across multiple studies. Then,
he objective was to compare the ACCF/AHA methodology
ith some other prominent methodologies in current use, such as
Table 4.2. Clinical Practice Guideline Grading Models (ACCF/A
ACCF/AHA GRADE
trength of Recommendation I (Strong) Strong
evel of Evidence* A High
B Moderat
C Low
trength of Recommendation IIa (Moderate) Weak
evel of Evidence* A High
B Moderat
C Low
trength of Recommendation IIb (Weak) Weak
evel of Evidence* A High
B Moderat
C Low
trength of Recommendation III: No Benefit OR
Harm
(Against)
Strong or
Weak
evel of Evidence* A High
B Moderat
C Low
evel of Evidence*
ACCF indicates American College of Cardiology Foundation; ACP, American College of Physicians
and Evaluation; NHLBI, National Heart, Lung, and Blood Institute; and USPTF, U.S. Preventive S
*The ACCF/AHA level of evidence nomenclature identifies the type of evidence and correlates
or expert opinion. Other guideline developers incorporate the quality of evidence to imply a more de
of the data defined as high, moderate, or low. Although determining the quality of studies inform
the nomenclature used by the ACCF/AHA is not meant to be synonymous with overall quality ofRADE, NHLBI, and AHRQ EPC (Tables 4.2 to 4.7). Thefinal goal then was to recommend whether and what
practical changes/additions might be made to current
ACCF/AHA COR/LOE methodology to improve its clar-
ity and accuracy.
Review of COR/LOE Versus Other Methodologies
Professional societies that write CPGs typically provide the
end user with a recommendation that has 2 dimensions. The
first dimension is a statement of the strength of the recom-
mendation, signifying the GWC’s synthesized interpretation
of the evidence with respect to how strongly the committee
believes that the action/treatment may contribute to providing
optimum care of a patient with the target condition discussed
in the CPGs. The second dimension is a statement about the
strength of the evidence on which the recommendation is
based. The purpose of the strength of evidence component is
to offer the end user insight into the range and type of evidence
reviewed by the GWC when formulating the recommenda-
tion. The strength of recommendation and strength of evi-
dence notations are provided in a hierarchical scheme that is
ordinal and does not imply any mathematical relationship
along the continuum of recommendations. The scheme by
which the ordinal bins are depicted to end users varies by
Interpretation)
USPTF NHLBI ACP
A A-Strong Strong
High High High
Moderate Moderate Moderate
Low Low Low
B B-Moderate Weak
High High High
Moderate Moderate Moderate
Low Low Low
C C-Weak Weak
High High High
Moderate Moderate Moderate
Low Low Low
D D-Against Strong or
Weak
High High High
Moderate Moderate Moderate
Low Low Low
Iinsufficient Eexpert opinion Iinsufficient
Nno recommendation
American Heart Association; GRADE, Grading of Recommendations Assessment, Development,
Task Force.
pecific number, type and quality of studies, for example, randomized trials, observational data,
ualitative and quantitative way of combining data from individual studies into an overall synthesis
ommendations within each level of evidence is inherent to the ACCF/ACC process, at this time
dy of evidence. It will be modified once an evidence grading tool is completed.HA
e
e
e
e
; AHA,
ervices
to a s
fined qorganization and may contain combinations of numbers, let-
B only
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order intended by the GWC.
Although the universally agreed-on purpose of CPGs is
to offer an instruction set to clinicians caring for patients, it
is also understood that individual clinical circumstances may
necessitate deviation from the recommended path. Clini-
cians are advised to document their reasons for deviation
from the recommendations. Beyond these straightforward
statements, there is variation in how organizations view the
intended use of their CPGs. Some organizations write their
CPGs with anticipation that they will be intended for end
users beyond clinicians, including policy makers respon-
Table 4.3. Applying Classification of Recommendations and Le
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak
Although randomized trials are unavailable, there may be a very clear clinical consensus that a
Data available from clinical trials or registries about the usefulness/efficacy in different subp
failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and
treatments or strategies being evaluated.sible for reimbursement for medical care and even pa-tients themselves. When such extended targets of the
recommendations are contemplated by GWCs, the in-
structions include consideration of resources and per-
ceived patient preferences.
Perspective on ACCF/AHA CPG Grading System
Relative to Other Systems
With the background noted previously, it is useful to reflect
on the ACCF/AHA CPG grading system. The intended
audience is clinicians in North America caring for patients
with cardiovascular disease. Although it is anticipated that
the recommendations may be read with interest by policy
f Evidence
important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
lar test or therapy is useful or effective.
ons, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
), studies that support the use of comparator verbs should involve direct comparisons of thevel o
. Many
particu
opulatimakers and even patients, the instructions to GWCs for
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the wording of recommendations take into account cost or
patient preferences (although the GWC addresses the latter
in each preamble, noting that patients should be informed
Table 4.4. GRADE System, As Adapted by ACCP
Grade of
Recommendation* Benefit vs Risk and Burdens
Meth
trong recommendation,
high-quality evidence,
Grade 1A
Desirable effects clearly outweigh
undesirable effects, or vice
versa
Consis
impo
stro
stud
trong recommendation,
moderate-quality
evidence, Grade 1B
Desirable effects clearly outweigh
undesirable effects, or vice
versa
Eviden
limit
met
imp
from
trong recommendation,
low or very low-quality
evidence, Grade 1C
Desirable effects clearly outweigh
undesirable effects, or vice
versa
Eviden
outc
case
serio
eak recommendation,
high-quality evidence,
Grade 2A
Desirable effects closely balanced
with undesirable effects
Consis
impo
stro
stud
eak recommendation,
moderate-quality
evidence, Grade 2B
Desirable effects closely balanced
with undesirable effects
Eviden
limit
met
imp
from
eak recommendation,
low or very low-quality
evidence, Grade 2C
Desirable effects closely balanced
with undesirable effects
Eviden
outc
case
serio
*We use the wording we recommend for strong (Grade 1) recommendations and we suggest fo
CCP indicates American College of Chest Physicians; GRADE, Grading of Recommendations A
Reproduced from Guyatt et al. (17).
Table 4.5a. USPTF Recommendation Grading System
Grade Definition
A The USPSTF recommends the service. There is high certainty th
benefit is substantial.
B The USPSTF recommends the service. There is high certainty th
benefit is moderate or there is moderate certainty that the n
moderate to substantial.
C Note: The following statement is undergoing revision.
Clinicians may provide this service to selected patients depe
individual circumstances. However, for most individuals with
symptoms there is likely to be only a small benefit from this
D The USPSTF recommends against the service. There is modera
certainty that the service has no net benefit or that the harm
benefits.
I Statement The USPSTF concludes that the current evidence is insufficient
balance of benefits and harms of the service. Evidence is lac
quality, or conflicting, and the balance of benefits and harms
determined.
The USPSTF updated its definitions of the grades it assigns to recommendations and now include
regarding net benefit. These definitions apply to USPSTF recommendations voted on after MayUSPSTF indicates U.S. Preventive Services Task Force.
Reproduced from U.S. Preventive Services Task Force (18).of the risks, benefits, and alternatives to a particular treat-
ment and should be involved in shared decision making
whenever feasible, particularly for COR IIa and IIb, where
the benefit-to-risk ratio may be lower). The GWC may
ic Quality of Supporting
Evidence Implications
idence from RCTs without
limitations or exceptionally
dence from observational
Recommendation can apply to most patients
in most circumstances; further research is
very unlikely to change our confidence in
the estimate of effect
RCTs with important
(inconsistent results,
gic flaws, indirect or
), or very strong evidence
rvational studies
Recommendation can apply to most patients
in most circumstances; higher quality
research may well have an important
impact on our confidence in the estimate
of effect and may change the estimate
at least one critical
rom observational studies,
s, or from RCTs with
ws or indirect evidence
Recommendation can apply to most patients
in many circumstances; higher-quality
research is likely to have an important
impact on our confidence in the estimate
of effect and may well change the
estimate
idence from RCTs without
limitations or exceptionally
dence from observational
The best action may differ depending on
circumstances or patient or society values;
further research is very unlikely to change
our confidence in the estimate of effect
RCTs with important
(inconsistent results,
gic flaws, indirect or
), or very strong evidence
rvational studies
Best action may differ depending on
circumstances or patient or society values;
higher-quality research may well have an
important impact on our confidence in the
estimate of effect and may change the
estimate
at least one critical
rom observational studies,
s, or from RCTs with
ws or indirect evidence
Other alternatives may be equally
reasonable; higher-quality research is
likely to have an important impact on our
confidence in the estimate of effect and
may well change the estimate
(Grade 2) recommendations.
ent, Development and Evaluation; and RCTs, randomized controlled trials.
Suggestions for Practice
net Offer or provide this service.
net
efit is
Offer or provide this service.
on
ns or
e.
Offer or provide this service only if other considerations support
the offering or providing the service in an individual patient.
igh
eigh the
Discourage the use of this service.
ess the
of poor
ot be
Read the clinical considerations section of USPSTF
Recommendation Statement. If the service is offered,
patients should understand the uncertainty about the
balance of benefits and harms.
estion for practice” associated with each grade. The USPSTF has also defined levels of certaintyodolog
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implications, but such considerations are not intended to
drive the wording of a recommendation. Underlying the
ACCF/AHAmethodology for CPG development is a set of
considerations for focusing the ACCF/AHA recommenda-
tions specifically on the science of the data and are: 1) to
reserve a place in the set of instructions for clinicians where
science trumps other considerations because cost is dynamic
and variable from system to system, 2) to allow those bodies in
our society that determine how resources are to be allocated to
have a reference point for the science review, and 3) in the
absence of formal patient data using time tradeoffs and utility
function testing, it is difficult to describe with certainty the
distribution of patient preferences.
Table 4.5b. USPTF Levels of Certainty Regarding Net Benefit
Level of Certainty*
igh The available evidence usually includes consist
populations. These studies assess the effe
unlikely to be strongly affected by the res
oderate The available evidence is sufficient to determin
estimate is constrained by such factors as
● The number, size, or quality of individual st
● Inconsistency of findings across individual s
● Limited generalizability of findings to routin
● Lack of coherence in the chain of evidence
As more information becomes available, the m
large enough to alter the conclusion.
Low The available evidence is insufficient to assess
● The limited number or size of studies.
● Important flaws in study design or methods
● Inconsistency of findings across individual s
● Gaps in the chain of evidence.
● Findings not generalizable to routine prima
● Lack of information on important health ou
More information may allow estimation of effe
*The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a
as implemented in a general, primary care population. The USPSTF assigns a certainty level ba
USPSTF indicates U.S. Preventive Services Task Force.
Reproduced from U.S. Preventive Services Task Force (18).
Table 4.6. NHLBI Evidence Grading System
Evidence Quality Grading and Recommendation Strength
Evidence Quality for Each ES Strength of Each Recommendation
igh A – Strong
● Well-designed and conducted RCTs B – Moderate
oderate C – Weak
● RCTs with minor limitations D – Against
● Well-conducted observational
studies
E – Expert Opinion
N – No Recommendation
Low
● RCTs with major limitations
● Observational studies with major
limitations
ES indicates evidence statement; NHLBI, National Heart, Lung, and Blood Institute; and RCTs,
randomized controlled trials.
Reproduced from Smith (19).As with the other grading schemes, recommendations
with the largest estimated size of intervention effect in
clinical practice are those that are the strongest for (green
rows in accompanying Table 4.3) or against (red rows in
accompanying Table 4.3) providing an intervention be-
cause of lack of benefit or even some evidence of harm.
All other recommendations are discretionary, and clinical
responses to them are heavily influenced by the charac-
teristics of the patient and the circumstances surrounding
that patient’s care.
There are no rigorously performed studies comparing the
consequences of clinical actions that adhere to recommen-
dations provided in one scheme versus another. Data are
available, largely from registry reports, that adherence to the
current ACCF/AHA system (Table 4.3), which is familiar
to cardiovascular clinicians worldwide and drives ACCF/
AHA performance measures, is associated with improved
patient outcomes (11,12). In the absence of evidence of
superiority of one grading system over another, a decision
was made to retain the current ACCF/AHA COR/LOE
structure and nomenclature, with minor modifications to
“map” to terminology in other well-known grading systems.
Data from individual studies and multiple studies (pooled
by either the random effects or fixed effects methods) can be
accommodated by the current ACCF/AHA system.
4.4. Workgroup 4 Recommendations Regarding
ACCF/AHA Grading Methodology and Nomenclature
1. Retain the current basic ACCF/AHA COR and LOE
Description
sults from well-designed, well-conducted studies in representative primary care
the preventive service on health outcomes. This conclusion is therefore
future studies.
effects of the preventive service on health outcomes, but confidence in the
.
ary care practice.
de or direction of the observed effect could change, and this change may be
s on health outcomes. Evidence is insufficient because of:
.
practice.
s.
health outcomes.
tive service is correct” The next benefit is defined as benefit minus harm of the preventive service
the nature of the overall evidence available to assess the net benefit of a preventive service.ent re
cts of
ults of
e the
:
udies.
tudies
e prim
.
agnitu
effect
.
tudies
ry care
tcome
cts on
preven
sed onstructure/nomenclature.
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validated ACCF/AHAEvidenceGrading Tool (under devel-
opment) that will incorporate features of existing tools.
3. Change the wording of LOE to Quality of Evidence
(QOE) (once the ACCF/AHA Evidence Grading Tool is
operational).
4. Add a separate category for QOE: E (expert opinion),
and generate specific definitions and examples for
Table 4.7. Interpretation of the ACP Guideline Grading System
Grade of
Recommendation
Benefit Versus Risks and
Burdens
Methodological
Supporting Ev
trong recommendation;
high-quality evidence
Benefits clearly outweigh risks
and burden or vice versa
RCTs without import
or overwhelming e
observational stud
Strong recommendation;
moderate-quality
evidence
Benefits clearly outweigh risks
and burden or vice versa
RCTs with important
(inconsistent resu
methodological fla
or imprecise) or ex
strong evidence fr
observational stud
Strong recommendation;
low-quality evidence
Benefits clearly outweigh risks
and burden or vice versa
Observational studie
series
Weak recommendation;
high-quality evidence
Benefits closely balanced with
risks and burden
RCTs without import
or overwhelming e
observational stud
Weak recommendation;
moderate-quality
evidence
Benefits closely balanced with
risks and burden
RCTs with important
(inconsistent resu
methodological fla
or imprecise) or ex
strong evidence fr
observational stud
Weak recommendation;
low-quality evidence
Benefits closely balanced with
risks and burden
Observational studie
series
Insufficient Balance of benefits and risks
cannot be determined
Evidence is conflictin
quality, or lacking
ACP indicates American College of Physicians; and RCTs, randomized controlled trials.
Reproduced from Qaseem et al. (20).QOE: E.5. Change “Treatment Effect” on the COR/LOE table to
“Intervention Effect” and indicate that “Intervention”
includes medications, devices, therapeutic strategies,
procedures, diagnostic tests, and other.
6. Add adjectives that “map” COR/LOE to the NHLBI (and
GRADE) (i.e., I [strong]; IIa [moderate]; IIb [weak]; III
[against]).
7. Take every opportunity to align COR as closely as
y of
e Interpretation Implications
itations
ce from
For patients, most would want the
recommended course of action
and only a small proportion
would not; a person should
request discussion if the
intervention was not offered.
Strong recommendation; can
apply to most patients in most
circumstances without
reservation
For clinicians, most patients
should receive the
recommended course of action.
For policymakers, the
recommendation can be
adopted as a policy in most
situations.
tions
direct,
nally
se Strong recommendation but may
change when higher-quality
evidence becomes available
itations
ce from
For patients, most would want the
recommended course of action
and only a small proportion
would not—a decision may
depend on an individual’s
circumstances.
tions
direct,
nally
Weak recommendation; best
action may differ depending
on circumstances or patients’
or societal values
For clinicians, different choices
will be appropriate for different
patients, and a management
decision consistent with a
patient’s values, preferences,
and circumstances should be
reached.
se Very weak recommendations;
other alternatives may be
equally reasonable
For policymakers, policymaking
will require substantial debate
and involvement of many
stakeholders.
r Insufficient evidence to
recommend for or against
routinely providing the service
For patients, decisions based on
evidence from scientific studies
cannot be made.
For clinicians, decisions based on
evidence from scientific studies
cannot be made.
For policymakers, decisions based
on evidence from scientific
studies cannot be made.Qualit
idenc
ant lim
viden
ies
limita
lts,
ws, in
ceptio
om
ies
s or ca
ant lim
viden
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other major grading systems (e.g., Table 4.2).
Additional Comments:
1. Plan for regular review (e.g., annually) of CPG recom-
mendations and modify as appropriate.
2. Develop a list of metrics that should be measured and
assessed.
4.5. Workgroup 4 Additional Recommendations
Workgroup 4 recommends that additional assessment of the
methodological quality (risk of bias) in individual studies, as well as
an evaluation of essential characteristics of quality across the body
of evidence, by outcome, be incorporated into a qualitative
synthesis of evidence inACCF/AHACPGs.To accomplish this,
Workgroup 4 recommends the following:
1. Consider use of a standardized tool, such as theCochraneRisk
of Bias Tool, for assessing risk of bias within and across studies
(10). For observational studies, use a tool that specifically
evaluates the methodological limitations of such studies, such
as risk of selection bias, potential confounding factors that may
affect the estimate of effect, and biases in the design and
execution of nonrandomized studies. The Cochrane Collabo-
ration is currently modifying its Risk of Bias tool for use in
nonrandomized studies.
2. For assessment of consistency, precision, directness,
reporting bias, and, with observational studies, large
magnitude of effect, a dose-response association, or
confounding factors that would change the reported
effect, follow the GRADE or AHRQ definitions for
assessment of each characteristic across the body of
evidence for each outcome.
3. Consider depicting the summary evaluation of the qual-
ity characteristics for a body of evidence in a table format.
Use the GRADE evidence profiles and summary of
findings tables as models of table formats.
4. In addition to summary quality evaluation tables, provide a
high-level narrative synthesis of the quality of a body of
evidence that includes the IOM’s 4 elements of performance
for conducting a qualitative synthesis, as described above.
5. Workgroup 5: Standards for Reporting
Systematic Reviews
See Workgroup 5 Comparison Table.
(Authors: Dr. E.Magnus Ohman, Chair; Drs. Deepak L. Bhatt, Kay
Dickersin, Raymond J. Gibbons, and William G. Stevenson)
CPGs have become an important part of the practice of
cardiology and other aspects of healthcare delivery. They
represent some of the most downloaded and quoted papers
published in the literature and therefore are of major
importance to the practicing clinician. Furthermore, several
outcomes studies have suggested that adherence to ACCF/
AHA CPGs is associated with both better in-hospital aswell as long-term outcomes (11,12,21). There are 2 crucial
factors for dissemination and acceptance of CPGs. They
need to be readable and not merely tables of synthesized
information. They should also allow the reader to under-
stand the logic and process of evidence synthesis to form
coherent recommendations that inform the practice of
medicine (22). Therefore, in producing CPGs, GWCs need
to recognize that although the body of data for a recom-
mendation ranges from minimal to extensive; the presenta-
tion must be comprehensive, logical, and readable to be a
relevant resource for clinical practice.
As recommended throughout this report, our goal is for
SR to underpin our CPG recommendations. Recognizing
that it is not possible to complete SR for all CPGs over a
short period of time, we recommend that our CPGs be
transformed sequentially, with SR being sought or per-
formed first for those topics deemed to be of greatest
importance. When high-quality SRs are available and up to
date, they should be summarized and used as a basis for our
CPGs. In the event that “conflicting” meta-analyses have
been published, thoughtful consideration should be given to
developing a formal SR to provide clarity and therefore
enable better recommendations for the CPGs. When high-
quality SRs do not exist or an update is needed, the
ACCF/AHA could commission a new review. In cases
where an SR has been determined to be of lower importance
to other topics at that time, an informal assessment of
evidence combined with expert opinion is conducted.
On occasion, SR may be performed on topics for which
there are few or no RCTs. With only 1 trial or a few small
trials, one is not sure whether reporting biases may threaten
the validity of the summary findings. Where no RCTs exist
and the question of intervention effectiveness is important
or RCTs are difficult to perform (e.g., during cardiac arrest),
investigators may decide to seek data from observational
studies such as analysis of administrative or registry data. SR
of observational studies are potentially more complex than
SR of RCTs, as searching methods for observational studies
are not well established and important observational data
could be missed. In addition, observational studies are
subject to selection and other forms of bias that can make
their findings difficult to interpret. Thus, SR of observa-
tional data should be used sparingly and will require careful
review (see Workgroups 2, 3, and 4).
Incorporating Systematic Reviews as Part of the CPGs
CPGs are, by design, summaries of SRs that can be quite
lengthy and detailed. In areas such as hypertension or
prevention, for example, literally hundreds of studies are
potentially eligible for SR of intervention effectiveness.
With the use of methods for summarizing all relevant data,
an SR fully encapsulates information in a condensed format
that can be translated into CPGs.
In the early 1990s, the AHRQ supported the University
of California San FranciscoStanford EPC to partner with
the ACCF/AHA team producing the “ACC/AHA/
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ternal Medicine Guidelines for the Management of Patients
with Chronic Stable Angina,” published in 1999 (23,24).
n EPC representative of that group attended the meetings
f the GWC, and the EPC made several contributions to
he CPG. First, the EPC performed a number of small
iterature searches that led to studies being incorporated into
he CPG, for example, a summary of RCTs and meta-
nalyses of garlic therapy for treatment of risk factors
ppeared in the tables and figures of the final CPG. The
argest portion of the work done by the EPC was a careful
R of the evidence for medical therapy for chronic stable
ngina and, in particular, comparisons of the commonly
sed drugs (beta blockers and calcium antagonists) that were
sed in the treatment of chronic stable angina. This was
ublished separately (24). An example of incorporating a
alient summary of the EPC finding into the text of the
PG is shown in Tables 5.1a and 5.1b, and Figures 5.1a
nd 5.1b. This approach allowed the natural flow of the
PG to be maintained and allows the complete SR,
Table 5.1a. RCTs and Meta-Analyses of Garlic Therapy for Risk
Author Year Study Type Patien
Hypercholesterolemia
Berthold 1998 RCT 25*
Isaacsohn 1998 RCT 40
Jain 1993 RCT 42
Warshafsky 1993 Meta-analysis 5 trial
ypertension
Silagy
1994 Meta-analysis 8 trial
Cross-over study.
BP indicates blood presssure; LDL, low-density lipoprotein; and RCT, randomized controlled t
Reproduced from Gibbons et al. (24).
Table 5.1b. RCT in Stable Angina Comparing Beta Blockers an
Trial Author Journal Year N
Beta Blocker
ARM 1 n 
Ca-Blocke
ARM 2 n
PSIS/Rehnqvist Eur Heart J 1996 809 Metoprolol* 406 Verapamil 4
IBET/Dargie Eur Heart J 1996 458 Atenolol 226 Nifedipine* 2
MAGE/Savonitto JACC 1996 127 Metoprolol* 65 Nifedipine* 6
e Vries Int J Card 1996 128 Atenolol 66 Nifedipine* 6
IBBS/Von Arnim JACC 1995 330 Bisoprolol 161 Nifedipine* 1
huja Int J Card 1993 134 Metoprolol 68 Diltiazem 66
otal 1,986 992 994
Long-acting preparations.
APSIS indicates Angina Prognosis Study in Stockholm; IMAGE, International Multicenter AngIschemic Burden Bisoprolol Study; and TIBET, Total Ischaemic Burden European Trial.
Reproduced from Gibbons et al. (24).representing original research on its own, to be published
independently.
Independent review of SRs in addition to that of CPGs
is an important check on scientific rigor and validity. We
believe that the independent review performed in the
course of consideration for publication achieves this aim.
Previously completed SRs that have been published in a
peer-reviewed journal already meet this standard. We
recommend that a newly commissioned SR also be
published separately and independently from the CPGs
and subject to the journal’s peer review process, which
will ensure that they are of the highest standard. Inde-
pendent publication would also allow the academic group
that is charged with performing the SR to achieve
academic recognition for its work. However, independent
publication does create challenges. Ideally, the SR should
be accepted and at least in press before it is incorporated
into the CPGs so that any changes in response to peer
review have been included. The publication of SR find-
ings separately from evidence that is based on the SR and
atment of Risk Factors
Daily Dose and
Preparation Effect of Garlic
10 mg steam distilled oil No difference in multiple measures
900 mg powder No difference in multiple measures
900 mg powder Reduction in LDL of 11% vs. 3% for
placebo
1/2–1 clove per day Reduction in total cholesterol of
95 mg/dL
600–900 mg powder Small reduction in systolic and
diastolic BP
lcium Antagonists
Follow Up Outcome
Results
ARM 1 n 
Result
ARM 2 n 
Odds Ratio
ARM 2/ARM 1
for Death or MI
3.4 y Death 22 25 1.01 (0.63, 1.6)
Cardiac death 19 19
Nonfatal MI 17 14
2 y Cardiac death 3 6 1.22 (0.63, 2.4)
Nonfatal MI 14 15
6 wk Death 1 0 0.5 (0.05, 5.8)
Nonfatal MI 1 1
4 wk Nonfatal MI 0 1 1.07 (0.2, 55)
4 wk Nonfatal MI 0 1 1.91 (0.06, 57)
4 wk Death or MI 0 0 1.03 (0.02, 53)
Death or MI Summary OR
58 62 1.06 (0.73, 1.54)
rcise; MI, myocardial infarction; OR, odds ratio; RCT, randomized controlled trial; TIBBS, TotalTre
ts
s
sd Ca
r

03
32
2
2
69
ina Exe
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ACCF/AHA Guideline Methodology Summit Report January 15, 2013:213–65Figure 5.1a. Beta Blockers Versus Ca Antagonists: Angina ReliefReproduced from Gibbons et al. (24).Figure 5.1b. Beta Blockers Versus Calcium Antagonists Exercise Time to 1-mm ST DepressionReproduced from Gibbons et al. (24).
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duplicate publication. The ACCF/AHA CPGs focus on
the summary information and any salient figures or tables
that are included are modified and cited appropriately.
Perhaps, a more difficult issue relates to the timing of
publication and embargo. Although publication of the
SR potentially provides a preview of information from
the CPGs to interested parties, we do not feel that this
would diminish the CPGs, as the SR is only a portion of
the information that will be provided in the CPG and
does not include recommendations and additional clinical
synthesis. SRs do not make practice recommendations;
they are simply a summary of relevant data addressing a
clinical question. The GWC will provide COR/LOE on
review of the SR and in conjunction with other recom-
mendations applicable to a similar clinical setting. Thus,
the SR and CPG can be developed simultaneously (with
potential edits/revisions made in response to peer review)
and the SR published before, without embargo, or nearly
simultaneously with the CPG.
Discordance between the ERC and the GWC will be
resolved through liaison committee members (see Work-
group 2). A key feature of the review will be transparency.
The GWC should specifically cite the SR and indicate how
it was incorporated into the CPG.
Guideline Review Tables in the Absence
of a Systematic Review
Because SR will not initially be possible for all recommen-
dations, it will be important to distinguish recommenda-
tions based on SR from those based on narrative reviews
and/or expert opinion. For transparency, the evidence base
for recommendations based on non-systematically collected
information should be provided in summary tables called
“CPG review tables” as well. Items presented would be
similar to those presented for trials included in the SR
evidence tables, for example, characteristics of the individual
studies and factors that allow an assessment of potential bias
(i.e., study “quality”), measures of effect size for each study,
and list of primary and secondary outcomes reported.
Particular attention will be paid to ensuring that all relevant
studies are included and that the components noted above are
included. CPG review tables from nonsystematic reviews
should not be given more prominence than evidence tables
from SRs and so can be referred to in the text but are better
placed in online data supplements. It is important, though, that
the printed or online text, tables, and figures summarize the
information to enhance readability of the document and that
the recommendations flow naturally from the text. The com-
ponents of such tables and examples are listed in Table 5.2.
Like the evidence tables from SRs, the CPG review tables will
undergo peer review as part of the standard review process.
5.1. Workgroup 5 Recommendations
CPGs are strengthened when they are based on SR. Because it is
not possible to complete SR immediately for all questions covered Ta S
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fashion in order of importance of the question. Non-SRs and
accompanying summary tables will be used for areas where SRs
are not yet completed; however, SRsmay be performed over time.
It is believed that this combinationwill bring the current approach
of the ACCF/AHA CPGs in compliance with the recommen-
dations of the IOM, yet allow the CPGs to be readable, timely,
and relevant.
1. SRs included in CPGs should be published as separate
peer-reviewed manuscript(s) when feasible. By doing so,
all of the recommendations regarding methodology, peer
review, and access will be compliant with the IOM
recommendations (2).
2. Recommendations supported by SR should be identified
in CPGs in addition to the appropriate class and LOE.
Example: (Class I; LOE: A)SR.
. Within the CPG, salient tables and figures from SRs should
be included to support recommendations. The remaining
pieces of methodology will be hyperlinked to the original SR
publication. By doing so, key elements of the SR will be
available for public access once the CPG are published.
. CPG review tables should be incorporated into CPGs
for nonSR-based recommendations and be available as
online supplement tables.
. CPG review tables should incorporate the majority of
study components that are provided in SR tables.
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The following tables present each element proposed by the IOM and the Workgroups’ comments and recommendations forGuidelines We Can Trust
rrent Methodology Workgroup 1 Proposal
logy Manual (4) and
le to the public on the
tes. Selected processes are
reamble published with
The ACCF/AHA CPG methodology is currently
compliant.
ry detailed RWI policy that
d.
Patient representatives and all other GWC members
should explicitly declare any intellectual bias or
perspective for any topic covered by the
guideline. The GWC chair is responsible for
balancing competing intellectual perspectives
during deliberations and in the final document.
ry detailed RWI policy that
d.
The ACCF/AHA CPG methodology is currently
compliant.
ry detailed RWI policy that
d.
The ACCF/AHA CPG methodology is currently
compliant.
ry detailed RWI policy that
d.
The ACCF/AHA CPG methodology is currently
compliant.
icy does not require
res that RWI be balanced
riately.
Divestment is not required by ACCF/AHA policy.
See Section 2.3
quires that a majority of
e chair) have no relevant
The ACCF/AHA policy requires that a majority of the
GWC (including the chair) have no relevant RWI.
ry detailed RWI policy that
d.
The ACCF/AHA CPG methodology is currently
compliant.
quires that a majority of
e chair) have no relevant
The ACCF/AHA CPG methodology is currently
compliant.
not have relevant RWI, but
ted to do so.
The ACCF/AHA CPG methodology is currently
compliant.
t allow any outside funding
.
The ACCF/AHA CPG methodology is currently
compliant.each element.
Workgroup 1 Comparison Table
1. Clinical Practice
IOM Standards and Elements ACCF/AHA Cu
. Establishing transparency
.1 The processes by which a CPG is developed and
funded should be detailed explicitly and publicly
accessible.
The ACCF/AHA Methodo
processes are availab
ACCF and AHA websi
also detailed in the p
each CPG.
. Management of COI
.1 Prior to selection of the Guideline Development
Group (GDG), individuals being considered for
membership should declare all interests and
activities potentially resulting in COI with
development group activity, by written
disclosure to those convening the GDG.
The ACCF/AHA has a ve
includes this standar
● Disclosure should affect all current and
planned commercial (including services from
which a clinician derives a substantial
proportion of income), noncommercial,
intellectual, institutional, and patient/public
activities pertinent to the potential scope of
the CPG.
The ACCF/AHA has a ve
includes this standar
2.2 Disclosure of COIs within GDG
● All COI of each GDG member should be
reported and discussed by the prospective
development group prior to the onset of their
work.
The ACCF/AHA has a ve
includes this standar
● Each panel member should explain how their
COI could influence the CPG development
process or specific recommendations.
The ACCF/AHA has a ve
includes this standar
2.3 Divestment
● Members of the GDG should divest
themselves of financial investments they or
their family members have in, and not
participate in marketing activities or advisory
boards of, entities whose interests could be
affected by CPG recommendations.
The ACCF/AHA RWI pol
divestment but requi
and managed approp
2.4 Exclusions See Section 2.3
● Whenever possible GDG members should not
have COI.
The ACCF/AHA policy re
the GWC (including th
RWI.
● In some circumstances, a GDG may not be
able to perform its work without members
who have COIs, such as relevant clinical
specialists who receive a substantial portion
of their incomes from services pertinent to
the CPG.
The ACCF/AHA has a ve
includes this standar
● Members with COIs should represent not
more than a minority of the GDG.
The ACCF/AHA policy re
the GWC (including th
RWI.
● The chair or co-chairs should not be a
person(s) with COI.
The chair/co-chairs may
a vice chair is permit
● Funders should have no role in CPG
development.
The ACCF/AHA does no
for CPG development
Guidelines We Can Trust
rrent Methodology Workgroup 1 Proposal
3
3 a multidisciplinary group
addition to clinicians and
ethodologist,
e, internist, and other
ns.
The ACCF/AHA CPG methodology is currently
compliant.
3 es not currently include
presentatives.
Inclusion of a patient representative in the GWC
(and on the Task Force) is recommended. Patient
representatives with IOM-defined “health literacy”
skills are preferred. Relevant RWI and intellectual
perspectives should be declared and managed by
the GWC chair. Patient representatives will be
expected to participate in the development of key
clinical questions, choices, and opportunities for
shared decision making by incorporating patient-
centered values and preferences, issues
concerning quality of life, and patient-oriented
summaries of recommendations.
3 es not currently include
presentatives
All nonprofessional members of the GWC should
avail themselves of the U.S. Cochrane Center and
CUE’s “Understanding Evidence-Based Healthcare:
A Foundation for Action” (9) or an equivalent
online learning module before accepting their
position.
4
4 evidence-review
t incorporate a formal SR,
ew by Workgroups 2–5.
Workgroups 3–5 will provide recommendations.
4 evidence-review
t incorporate a separate
r review by Workgroup 2.
Workgroup 2 will provide recommendations.
5
5 thodology uses COR/LOE
grading tool to review the
ce is being developed.
Workgroup 4 will provide recommendations.
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IOM Standards and Elements ACCF/AHA Cu
. GDG composition
.1 The GDG should be multidisciplinary and
balanced, comprising a variety of
methodological experts and clinicians, and
populations expected to be affected by the CPG.
The ACCF/AHA GWC is
that may include (in
clinical scientists) a m
pharmacologist, nurs
subspecialty physicia
.2 Patient and public involvement should be
facilitated by including (at least at the time of
clinical question formulation and draft CPG
review) a current or former patient and a
patient advocate or patient/consumer
organization representative in the GDG.
The ACCF/AHA GWC do
patients and public re
.3 Strategies to increase effective participation of
patient and consumer representatives, including
training in appraisal of evidence, should be
adopted by GDGs.
The ACCF/AHA GWC do
patients and public re
. CPG-SR intersection
.1 CPG developers should use SRs that meet
standards set by the IOM’s Committee on
Standards for Systematic Reviews of
Comparative Effectiveness Research.
Current ACCF/AHA CPG
methodology does no
and this is under revi
.2 When SRs are conducted specifically to inform
particular guidelines, the GDG and SR team
should interact regarding the scope, approach,
and output of both processes.
Current ACCF/AHA CPG
methodology does no
ERC, and this is unde
. Establishing evidence foundations for and rating
strength of recommendations
.1 For each recommendation, the following should
be provided:
● An explanation of the reasoning underlying
the recommendation, including:
X A clear description of potential benefits
and harms.
X A summary of relevant available evidence
(and evidentiary gaps), description of the
quality (including applicability), quantity
(including completeness), and consistency
of the aggregate available evidence.
X An explanation of the part played by
values, opinion, theory, and clinical
experience in deriving the
recommendation.
● A rating of the level of confidence in
(certainty regarding) the evidence
underpinning the recommendation.
● A rating of the strength of the
recommendation in light of the preceding
bullets.
● A description and explanation of any
differences of opinion regarding the
recommendation.
The ACCF/AHA CPG me
methodology.
In addition, an evidence
quality of the eviden
Guidelines We Can Trust
rrent Methodology Workgroup 1 Proposal
6
6 E methodology includes this The ACCF/AHA CPG methodology is currently
compliant.
6 dherence to a set language
ble, and recommendations
tense whenever possible.
The ACCF/AHA CPG methodology is currently
compliant.
7
7 elopment includes an
process.
cess does not currently
regularly include
s.
CPG should be provided to an expanded group of
external reviewers before publication. External
reviewers would comprise a full spectrum of
relevant stakeholders (in addition to the current
group of scientific and clinical content experts
and partnering, collaborating, and other relevant
professional societies), such as healthcare
specialty societies, agencies (e.g., federal
government), and representatives of the public.
7 d RWI) are known to the
ed as an appendix to the
See 7.1 above.
7 r review process is
sheets of all comments
al reviewers receive
mments during the
The ACCF/AHA CPG methodology is currently
compliant.
7 elopment process does not
ss to and review by the
The public posting for comment was considered by
the Workgroup. The CPG process very carefully
avoids undue influence and pressure from
external stakeholders during CPG development.
We value the confidentiality and embargo
policies of the organizations and are concerned
about the potential influence of industry and
others on the process that cannot be adequately
managed during public review.
8
8 cess currently includes the
eview period in the
nd notes that new
wed twice yearly.
The ACCF/AHA CPG methodology is currently
compliant.
8 cess includes review of all
he major medical meetings
nvironmental scan of other
d from the experts on the
The ACCF/AHA CPG methodology is currently
compliant.
8 from the major medical
y and an environmental
re is requested from the
t GWC. The decision to
G is made according to
nclude (among others)
omized data deemed
is of results having an
fety and efficacy
The ACCF/AHA CPG methodology is currently
compliant.
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IOM Standards and Elements ACCF/AHA Cu
. Articulation of recommendations
.1 Recommendations should be articulated in a
standardized form detailing precisely what the
recommended action is and under what
circumstances it should be performed.
The ACCF/AHA COR/LO
information.
.2 Strong recommendations should be worded so
that compliance with the recommendation(s)
can be evaluated.
The COR/LOE requires a
for each COR.
These verbs are actiona
are written in active
. External review
.1 External reviewers should comprise a full
spectrum of relevant stakeholders, including
scientific and clinical experts, organizations
(e.g., health care, specialty societies), agencies
(e.g., federal government), patients, and
representatives of the public.
The ACCF/AHA CPG dev
extensive peer review
However, the review pro
include the public or
government agencie
.2 The authorship of external reviews submitted by
individuals and/or organizations should be kept
confidential unless that protection has been
waived by the reviewer(s).
The reviewer names (an
GWC and are publish
guideline.
.3 The GDG should consider all external reviewer
comments and keep a written record of the
rationale for modifying or not modifying a CPG
in response to reviewers’ comments.
The ACCF/AHA CPG pee
managed with spread
and responses. Offici
responses to their co
adjudication process.
.4 A draft of the CPG at the external review stage
or immediately following it (i.e., prior to the
final draft) should be made available to the
general public for comment. Reasonable notice
of impending publication should be provided to
interested public stakeholders.
The ACCF/AHA CPG dev
include external acce
general public.
. Updating
.1 The CPG publication date, date of pertinent
systematic evidence review, and proposed date
for future CPG review should be documented in
the CPG.
The ACCF/AHA CPG pro
dates and evidence r
introduction section a
evidence will be revie
.2 Literature should be monitored regularly
following CPG publication to identify the
emergence of new, potentially relevant
evidence and to evaluate the continued validity
of the CPG.
The ACCF/AHA CPG pro
LBCTs presented at t
twice yearly and an e
literature is requeste
current GWC.
.3 CPG should be updated when new evidence
suggests the need for modification of clinically
important recommendation. For example, a
CPG should be updated if new evidence shows
that a recommended intervention causes
previously unknown substantial harm; that a new
intervention is significantly superior to a previously
recommended intervention from an efficacy or
harms perspective; or that a recommendation can
be applied to new populations.
All LBCTs are reviewed
meetings twice yearl
scan of other literatu
experts on the curren
update an existing CP
specific criteria that i
large RCT or nonrand
important on the bas
impact on current sa
assumptions.ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; COI, conflict of interest; COR, class of recommendation; CPG, clinical practice guideline; CUE, Consumers
United for Evidence Based Medicine; GDG, guideline development group; GWC, guideline writing committee; IOM, Institute of Medicine; LBCT, late-breaking clinical trial; LOE, level of evidence; RCT,
randomized controlled trial; RWI, relationships with industry and other entities; and SR, systematic review.
ting a Systematic Review
ethodology Workgroup 2 Proposal
form a formal SR
ds, but rather the
incorporated into
ve representation
including
A committee should be formed of individuals with appropriate
expertise in SR and the clinical content being reviewed. The
ERC and GWC should remain separate, but individuals
should not be excluded from serving on both in a liaison
role.
form a formal SR
ds, but rather the
incorporated into
ng on the CPG
methodologist
me GWC do
ith expertise
The ERC should potentially include a methodologist and/or
statistician with experience in scientific SR. If a formal SR
is necessary, an ERC to perform the review should be
organized, but if an SR is not necessary, the ACCF/AHA will
build on the current process by adding more experts to the
GWC. The GWC should be expanded with methodologists
and statisticians and include stakeholders and policy
makers.
2 form a formal SR
rds, but rather the
d incorporated
search terms, and
WC members,
es.
The ERC will be responsible for searching and identifying
evidence relevant to the CPG. In addition, a request should
be made to payers and policy makers (and other identified
stakeholders) to provide evidence relevant to the SR. The
GWC should be expanded; see 2.1.2. Consumers should
help with providing advice on specific topics that will affect
an SR.
2 form a formal SR
ds, but rather the
incorporated into
ng on the CPG
methodologist
me GWC do
ith expertise in
As stated in 2.1.2, the ERC should potentially include a
methodologist and statistician who have experience in
scientific SR.
2 form a formal SR
ds, but rather the
incorporated into
ng on the CPG
ique expertise,
d on GWC as
and pharmacists.
The members of the ERC may include experts from the health
field, that is, nurses, pharmacists, physician assistants, and
nurse practitioners in addition to essential stakeholders.
The ERC should include a librarian and/or an in-house
information specialist(s) who will work with the ERC and
GWC to plan the search strategy (see 3.1.1 in Workgroup 3
Comparison Table).
2
2 al RWI policy (4).
t is published in
along with the
e an official
ual bias, but it is
iation of each
de range of
brought to the
Members of the ERC and GWC will disclose all potential
relationships as required by the ACCF/AHA official RWI
policy (4) and be free of RWI and balanced with respect to
intellectual perspective.
For selected guideline topics, we recommend considering
expanding disclosure to include relevant
professional/intellectual or clinical practice perspectives in
the published document.
An ERC free of relevant RWI would be consistent with the IOM
recommendation, but the GWC RWI policy would remain
the same.
2 lude all
t RWI. Rather, a
WC in addition to
no relevant RWI.
Individuals with a clear financial conflict will be excluded from
membership in the ERC.
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2. Standards for Initia
IOM Standards and Elements ACCF/AHA Current M
2.1 Establish a team with appropriate expertise
and experience to conduct the SR
2.1.1 Include expertise in the pertinent clinical
content areas
The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. However, GWC ha
across all content areas,
pertinent clinical areas.
2.1.2 Include expertise in SR methods The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. However, dependi
topic and availability of a
with content expertise, so
include a methodologist w
in SR.
.1.3 Include expertise in searching for relevant
evidence
The ACCF/AHA does not per
according to IOM standa
literature is reviewed an
into a CPG.
GWC members provide key
then research staff and G
conduct literature search
.1.4 Include expertise in quantitative methods The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. However, dependi
topic and availability of a
with content expertise, so
include a methodologist w
quantitative methods.
.1.5 Include other expertise as appropriate The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. However, dependi
topic and the need for un
other experts are include
necessary, that is, nurses
.2. Manage bias and COI of the team
conducting the SR
.2.1 Require each team member to disclose
potential COI and professional or
intellectual bias
The ACCF/AHA has an offici
The definition of relevan
Appendix 1 of each CPG
authors’ RWI.
The ACCF/AHA does not hav
policy regarding intellect
discussed during the init
GWC to ensure that a wi
experts and opinions are
process.
.2.2 Exclude individuals with a clear financial
conflict
The ACCF/AHA does not exc
individuals with a relevan
minimum of 50% of the G
the GWC chair may have
ting a Systematic Review
ethodology Workgroup 2 Proposal
ve an official
al bias, but this is
ation of each
e range of
brought to the
Members of the ERC and GWC will disclose all potential
relationships as required by the ACCF/AHA policy (4). The
disclosure policy should be expanded to address relevant
professional/intellectual or clinical practice perspectives as
well so that the information is identified, included,
disclosed, and managed.
ve a separate SR The SR protocol should be open to stakeholder and public
review and comment. It is recommended that the
members of the ERC be responsible and make final
decisions about the design, analysis, and reporting of the
identified and selected data.
al RWI policy (4).
ce is published in
eline along with
ve an official
ual bias, but it is
iation of each
de range of
brought to the
Individuals providing input into the SR will disclose all
potential relationships as required by the ACCF/AHA official
RWI policy (4). These individuals should be free of RWI and
balanced with respect to intellectual perspective. The
disclosure policy should be expanded to address relevant
professional/intellectual or clinical practice perspectives as
well so that the information is identified, included,
disclosed, and managed.
ve an official
al bias, but this is
ation of each
e range of
brought to the
Individuals providing input into the SR will disclose all
potential relationships as required by the ACCF/AHA policy
(4). Input from individuals with professional or intellectual
bias would be excluded.
cess includes
nted at the major
early and an
her literature is
ts on the current
ate an existing
revised CPG) is
nd GWC
ria that include
or
med important on
cting current
ptions.
mpact multiple
elevant CPGs
in concordance.
SR topics should be generated in the historical fashion based
on new RCTs (LBCTs) and query of content experts.
A mechanism should be piloted that would allow the public
(stakeholders, policy makers, and payers) to submit
possible questions/topics for the CPG (initially, with a
focused approach to a confined topic). The decision to
update an existing CPG (or develop a new or revised CPG)
should be expanded to include the ERC.
PICO(TS)
AHA CPGs cover
d, the GWC
ensus on the
ve of the CPG.
PICO(TS) questions should be developed when new, revised,
or focused updates are being considered.
ogy Manual (4)
d to formulate
The ACCF/AHA CPG methodology is currently compliant.
ogy Manual (4)
d to formulate
The ACCF/AHA CPG methodology is currently compliant.
ogy Manual (4)
d to formulate
The ACCF/AHA CPG methodology is currently compliant.
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2.2.3 Exclude individuals whose professional or
intellectual bias would diminish the
credibility of the review in the eyes of the
intended users
The ACCF/AHA does not ha
policy regarding intellectu
discussed during the initi
GWC to ensure that a wid
experts and opinions are
process.
2.3. Ensure user and stakeholder input as the
review is designed and conducted
2.3.1 Protect the independence of the review
team to make the final decisions about
the design, analysis, and reporting of the
review
The ACCF/AHA does not ha
team.
2.4. Manage bias and COI for individuals
providing input into the SR
2.4.1 Require individuals to disclose potential
COI and professional or intellectual bias
The ACCF/AHA has an offici
The definition of relevan
Appendix 1 of each guid
the authors’ RWI.
The ACCF/AHA does not ha
policy regarding intellect
discussed during the init
GWC to ensure that a wi
experts and opinions are
process.
2.4.2 Exclude input from individuals whose COI
or bias would diminish the credibility of
the review in the eyes of the intended
users
The ACCF/AHA does not ha
policy regarding intellectu
discussed during the initi
GWC to ensure that a wid
experts and opinions are
process.
2.5 Formulate the topic for the SR
2.5.1 Confirm the need for a new review The ACCF/AHA guideline pro
review of all LBCTs prese
medical meetings twice y
environmental scan of ot
requested from the exper
GWC. The decision to upd
CPG (or develop a new or
made by the Task Force a
according to specific crite
(among others) large RCT
nonrandomized data dee
the basis of results impa
safety and efficacy assum
Recommendations that i
CPGs are updated in all r
simultaneously to mainta
2.5.2 Develop an analytic framework that
clearly lays out the chain of logic that
links the health intervention to the
outcomes of interest and defines the key
clinical questions to be addressed by
the SR
The GWC does not focus on
questions because ACCF/
broad topic areas. Instea
focuses on reaching cons
scope and clinical objecti
2.5.3 Use a standard format to articulate each
clinical question of interest
Checklist 1 in the Methodol
details the standards use
CPG objectives.
2.5.4 State the rationale for each clinical
question
Checklist 1 in the Methodol
details the standards use
CPG objectives.
2.5.5 Refine each question based on user and
stakeholder input
Checklist 1 in the Methodol
details the standards use
CPG objectives.
ting a Systematic Review
ethodology Workgroup 2 Proposal
form a formal SR
ds, but rather the
incorporated into
veloped from
or research
The ERC, with input from the GWC, should describe the
context and rationale for the review from both a decision-
making and research perspective and post this information
online.
form a formal SR
ds, but rather the
incorporated into
s include
riteria based on
MeSH searches.
The ACCF/AHA CPG methodology is currently compliant.
form a formal SR
ds, but rather the
incorporated into
broad-topic
C is to capture
me points,
rison groups of
The ACCF/AHA CPG methodology is currently compliant.
gy is described in
(Literature Search
The ACCF/AHA CPG methodology is currently compliant.
ized for each topic
quality of
The IOM standard should be followed.
completed.
endation
cluded in evidence
taff or GWC
The IOM standard should be followed.
2 part of the ACCF/ The IOM standard should be followed.
2 ding Tool is being
the analysis of
The ACCF/AHA Evidence Grading Tool should be used once
validity and reliability testing is completed.
2 C members. Workgroup 4 will provide recommendations.
2 C members. The current practice of rarely using differential treatment
effects according to patient subgroups to inform a
recommendation and only when prespecified, adequately
powered, and supported by heterogeneity testing should
remain.
2 are limited to the
blication of the
n, no time limits
unless the GWC
nt time frame is
on a diagnostic
st before a certain
to keep the range
The proposed time within which the SR will be conducted in
addition to the anticipated time for completion of the SR
protocol development and review should be described.
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2.6 Develop a systematic review protocol
2.6.1 Describe the context and rationale for the
review from both a decision-making and
research perspective
The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. No rationale is de
either a decision-making
perspective.
2.6.2 Describe the study screening and
selection criteria (inclusion/exclusion
criteria)
The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. Literature searche
inclusion and exclusion c
defined search limits for
2.6.3 Describe precisely which outcome
measures, time points, interventions, and
comparison groups will be addressed
The ACCF/AHA does not per
according to IOM standar
literature is reviewed and
a CPG. Because CPGs are
based, the goal of the GW
all outcome measures, ti
interventions, and compa
interest.
2.6.4 Describe the search strategy for
identifying relevant evidence
The guidelines search strate
the Methodology Manual
Methodology) (4).
2.6.5 Describe the procedures for study
selection
Study selection is individual
based on availability and
evidence.
2.6.6 Describe the data extraction strategy No explicit data extraction is
However, pivotal recomm
supporting evidence is in
tables created by either s
members.
.6.7 Describe the process for identifying and
resolving disagreement between
researchers in study selection and data
extraction decisions
This process is not currently
AHA methodology.
.6.8 Describe the approach to critically
appraising individual studies
An ACCF/AHA Evidence Gra
developed to systematize
individual studies.
.6.9 Describe the method for evaluating the
body of evidence, including the
quantitative and qualitative synthesis
strategies
This is done implicitly by GW
.6.10 Describe and justify any planned
analyses of differential treatment
effects according to patient subgroups,
how an intervention is delivered, or how
an outcome is measured
This is done implicitly by GW
.6.11 Describe the proposed timetable for
conducting the review
For CPG updates, searches
time period following pu
last version of the CPG.
For a new CPG or full revisio
on searches are imposed
determines that a differe
appropriate (e.g., a CPG
modality that did not exi
date). The preference is
to 10 years prior.
ting a Systematic Review
ethodology Workgroup 2 Proposal
undergo a public
r, a thorough peer
The current peer review process of ACCF/AHA CPGs should be
expanded to include a formal peer assessment of the SR
protocol. External stakeholders and patient representatives
should be included in this expanded process. Response to
selected comments, with changes made in protocol or
whether no changes were made, may be publicly reported
if not precluded by time constraints.
ultaneously
f the American
in Circulation.
The final SR protocol should be made publicly available and
amendments to the protocol added in a timely manner.
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2.7 Submit the protocol for peer review
2.7.1 Provide a public comment period for the
protocol and publicly report on disposition
of comments
The ACCF/AHA CPGs do not
comment period; howeve
review is conducted.
2.8 Make the final protocol publicly available,
and add any amendments to the protocol in
a timely manner
The ACCF/AHA CPGs are sim
published in the Journal o
College of Cardiology andACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; COI, conflict of interest; CPG, clinical practice guideline; ERC, evidence review committee; GWC, guideline
writing committees; IOM, Institute of Medicine; LBCT, late-breaking clinical trial; MeSH, medical subject heading; PICO(TS), mnemonic: population, intervention, comparator, outcomes, timing and
setting; RCTs, randomized controlled trials; RWI, relationships with industry and other entities; SR, systematic review; and Task Force, ACCF/AHA Task Force on Practice Guidelines.
nd Assessing Individual Studies
thodology Workgroup 3 Proposal
the SR process
rches. Three
nt in using
osely with the
rches with key
ext copies of
members
arches. Data
d for key studies.
The following are general recommendations for conducting SR:
● Given existing resources, conducting SR of evidence for the
entire scope of topics in an ACCF/AHA CPG may not be
feasible. Whenever possible, existing, high-quality SR
conducted by external groups (e.g., the Cochrane
Collaboration, AHRQ, and journal-based SR) should be used.
A search for SRs should be conducted at the beginning of the
guideline process.
● In the absence of existing SRs, a dedicated ERC, separate
from the GWC, should conduct de novo SR on a limited
number of clinical questions within a CPG. (Note: This
approach would initially be piloted with a focused approach
to a confined topic, perhaps with 1 or 2 ACCF/AHA Focused
Updates; see Workgroup 1).
● When selecting clinical questions for SR, the focus should be
on key levers in the process of care, especially on clinically
critical topics for which there may be substantial evidence
and/or a pressing need for guidance.
● When conducting a comprehensive SR is not feasible due to
resource or other constraints, the processes and procedures
used to review the evidence should be clearly described.
● The GWC and the ERC should define the population and
setting under consideration. In addition, the GWC and ERC
will prespecify topics of potential recommendations,
including potential interventions, comparators, and outcomes
for evidence review.
● Following the SR pilots on key clinical questions/topics:
1. the feasibility of conducting SR on a greater number of
topics within a guideline should be evaluated;
2. to maximize resources, the ACCF/AHA should consider
partnering with other organizations that conduct SR as
stand-alone products or to support guideline
development; and,
3. additional funding to contract with an EPC to conduct
SR should be considered.Workgroup 3 Comparison Table
3. Standards for Finding a
IOM Standards and Elements ACCF/AHA Current Me
3.1 Conduct a comprehensive, systematic
search for evidence
Two researchers are proficient in
and performing literature sea
project managers are proficie
PubMed. Researchers work cl
GWC to perform literature sea
search terms and obtain full-t
articles. However, some GWC
conduct their own literature se
supplement tables are create
nd Assessing Individual Studies
thodology Workgroup 3 Proposal
tions in PICO(TS)
, key search
CPG table of
n ask research
rches using a
er, some GWC
terature
It is recommended that all evidence searches be conducted by
trained staff research specialists. The ERC should include a
librarian and/or an in-house information specialist(s) who
will work with the ERC and the GWC to plan the search
strategy.
Training in developing comprehensive search strategies and
conducting searches should be provided to staff research
specialists (e.g., National Library of Medicine courses or
on-site training by an information specialist or librarian).
arch strategy
ts, a spreadsheet
in the previous
s have no time
arches for
ased on the time
of the CPG.
For each SR topic, the search should be structured based on a
clear clinical question described in the PICO(TS) format.
For all other clinical topics in the CPG, a PICO(TS)-like format
should be used to structure and clearly describe a broad
search strategy.
r examination,
nd key words.
Contracting with a librarian or information specialist on an as-
needed or project basis to review search strategies,
especially in the pilot phase, should be considered.
E, PubMed,
f trials on the
The ACCF/AHA CPG methodology is currently compliant.
articles” and
.
Citation indexes (e.g., Scopus and Web of Science) should be
searched whenever possible.
only considered
at a major
r than 2 years, 3)
endation, and 4)
bles (unless the
alth
by the Task Force
l references may
e GWC.
Reference lists of eligible studies should be reviewed to
identify additional relevant studies. Every effort should be
made to review all clinically relevant literature. Derivative
studies, secondary analyses, substudies, and confirmatory/
refuting research reports are by definition relevant but
provide a different LOE than the primary results of a
properly conducted clinical trial. Additional references may
be submitted to the ERC by the GWC.
tated in the CPG
are followed to
shed within the
diovascular
e English
red. ACCF/AHA
ently conduct
literature,
Task Force and
portant studies
ACCF/AHA staff research specialists currently conduct biannual
reviews of emerging literature, abstracts, and
presentations. Task Force and GWC members also identify
important studies and emerging literature.
Adjustments to the current focused update process might
include 1) creation of a calendar of prespecified dates,
roughly oriented around premier scientific meetings (ACCF/
AHA, ESC, HRS, and Transcatheter Therapeutics); 2)
delineation of a clear structure around who other than Task
Force members has input into the selection and
assessment of new data; and 3) consideration of a
mechanism using the website or a questionnaire to solicit
suggestions from ACCF/AHA members.
Automated processes, such as My NCBI in PubMed, should be
considered to rerun original searches for each clinical
question or topic on a regular basis.
If a focused update is to be the pilot of an SR, then the
appropriate PICO(TS) question would need formulation and
all relevant evidence (not just new evidence) would need to
be reviewed. A “focused” update does not imply a limited
SR. It does imply that the update question might be
adequately framed in a single PICO(TS) question for SR.
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3.1.1 Work with a librarian or other
information specialist trained in
performing SR to plan the search
strategy
No librarian is on staff. Key ques
format are not used; however
terms are used based on the
contents. GWC members ofte
staff to perform literature sea
literature search form; howev
members conduct their own li
searches.
3.1.2 Design the search strategy to
address each key research question
GWC members determine the se
using the CPG table of conten
of LBCTs, and literature used
CPG. New CPGs or full revision
limit on searches, whereas se
focused updates are limited b
following the last full revision
3.1.3 Use an independent librarian or other
information specialist to peer review
the search strategy
GWC members may provide pee
input into search strategies, a
3.1.4 Search bibliographic databases Databases used include MEDLIN
clinicaltrials.gov, and the list o
ACCF Cardiosource Web site.
3.1.5 Search citation indexes PubMed’s “search for additional
Google Scholar are both used
3.1.6 Search literature cited by eligible
studies
See 3.1.5. Unpublished data are
if the data were 1) presented
scientific meeting, 2) not olde
not used to support a recomm
not used in CPG figures and ta
data have important public he
implications; this is reviewed
on an-ad hoc basis). Additiona
be submitted to the ERC by th
3.1.7 Update the search at intervals
appropriate to the pace of generation
of new information for the research
question being addressed
The time period for searches is s
introduction. Articles in press
determine if they will be publi
CPG development period. Car
scientific meetings that use th
language are routinely monito
staff research specialists curr
biannual reviews of emerging
abstracts, and presentations.
GWC members also identify im
and emerging literature.
nd Assessing Individual Studies
thodology Workgroup 3 Proposal
cific databases Subject-specific databases should be reviewed as suggested by
the ERC and the GWC.
t the
rization to use
ned in its use.
EMBASE should be added to the list of routine databases to be
searched.
Other regional bibliographic databases should be added as
appropriate to the topic and/or as suggested by ERC and
GWC members.
ed include
the NCDR, FDA
scientific
te, ongoing trials
ublished
e addressed/
ch as MEDLINE/
l Trials Database,
lso searched.
The ACCF/AHA CPG methodology is currently compliant.
Another important source of information might be
postapproval clinical registries required by the FDA or CMS
for devices or drugs. Collaboration with the FDA or CMS
would be important in this regard.
The grey literature should be searched, especially for signals of
unreported safety issues. Lack of peer review is an issue
that needs consideration.
work jointly with
bility, study
ristics in order to
ary study
ut questions
If a large or important study is potentially downgraded by the
absence of information about study eligibility, study
characteristics, or control of bias, that study should be
flagged and an inquiry sent to authors. The corresponding
author would be the primary point person in this regard.
Unfortunately, this has the potential for continuation of bias
or introduction of additional bias, because the response of
the corresponding author might neither be audited nor peer
reviewed.
be approached
reported
ribed in the text
considered
ajor national or
g and data
C members may
g presenters to
, obtain
detailed reviews,
If important unpublished data are identified, the ERC should
request the data, document the request for additional
information, and report on the disposition of the request in
a publicly accessible appendix to the CPG.
ical journals
Medical
rnal of Medicine,
erican College of
re received
full-text articles
e sent
maintains
levant to
lopment.
The ACCF/AHA CPG methodology is currently compliant.
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3.1.8 Search subject-specific databases if
other databases are unlikely to
provide all relevant evidence
See 3.1.4. for search subject-spe
used.
3.1.9 Search regional bibliographic
databases if other databases are
unlikely to provide all relevant
evidence
EMBASE is currently not used, bu
department is obtaining autho
EMBASE, and staff will be trai
3.2 Take action to address potentially
biased reporting of research results
3.2.1 Search grey-literature databases,
clinical trial registries, and other
sources of unpublished information
about studies
Grey-literature databases search
monitoring registries such as
Websites, LBCTs presented at
sessions, and, when appropria
covered within guidelines. Unp
abstracts 2 years old may b
included. Online databases su
PubMed, Cardiosource Clinica
and the Cochrane library are a
3.2.2 Invite researchers to clarify
information related to study
eligibility, study characteristics, and
risk of bias
When necessary, GWC members
CPG staff to clarify study eligi
design, and/or study characte
refine literature searches. Prim
authors may be contacted abo
pertaining to the study.
3.2.3 Invite all study sponsors and
researchers to submit unpublished
data, including unreported outcomes,
for possible inclusion in the SR
Study sponsors/researchers may
about unpublished data or un
outcome, which may be desc
or data summary tables.
The results of unpublished data
include data presented at a m
international scientific meetin
presented 2 years prior. GW
also contact scientific meetin
ask questions, clarify matters
presentation slides, perform
or request general guidance.
3.2.4 Hand search selected journals and
conference abstracts
Tables of contents of major med
(e.g., Journal of the American
Association, New England Jou
The Lancet, Journal of the Am
Cardiology, and Circulation) a
weekly by guideline staff, and
pertinent to GWC members ar
electronically. Guideline staff
electronic copies of articles re
published CPG or CPG in deve
nd Assessing Individual Studies
thodology Workgroup 3 Proposal
GWC and CPG
ubMed,
nicaltrials.gov,
and Google
The ACCF/AHA CPG methodology is currently compliant.
e inclusion of
G introduction
imited to the
lished in a
ut translated into
G reference list
Medical
rt trials in French
les are identified
rted in
ference list.
The ACCF/AHA CPG methodology recommends inclusion of
studies published simultaneously in English and other
languages. However, studies published in a language other
than English and that do not include an English version are
neither translated nor included in the evidence reviews. It is
recommended that the ERC or GWC be permitted to
consider studies reported in languages other than English
for consideration.
on the basis of
criteria. The
of LBCTs also
e included or
ertinent to the
The ACCF/AHA CPG methodology should be more explicit in
identifying the prespecified criteria for inclusion or exclusion
of studies. The use of clinical questions in a PICO(TS) format
would facilitate this process.
lished articles
ervational
R). The majority
RCTs but also
s (i.e.,
udies, and
The ACCF/AHA CPG methodology is currently compliant.
Observational studies and databases of studies not completed
or published should be searched for potential harms of
intervention.
GWC members
th knowledge of
WC members. As
ach section may
multiple GWC
ning and
licitly done by
Dual screening and selection of eligible studies is currently not
conducted. To incorporate dual reviewing processes would
require additional staff.
Training a cadre of volunteer members to conduct dual reviews
as part of an overall ERC training program should be
considered.
ACCF/AHA members early in their academic careers may find
benefit in becoming involved in this process with no
financial remuneration. Academic credit might include
letters to department chairs and listing ERC members as
coauthors of the CPG along with the GWC.
iven an in-depth
ethodology
h orientation
ummary tables.
Written procedures and forms for screening and selecting
studies should be developed.
Members of the ERC who serve as screeners will need training
and verification of accuracy and consistency.
searches, and a
y reference and
ropriate GWC
relevant articles
arch analyst and
nal selection of
of the GWC
y used is not
Titles and abstracts of all articles should be screened, and then
the full text of potentially relevant articles identified in the
initial screening should be read.
The screening process should be conducted by the individuals
identified and trained as members of the ERC, separate
from the GWC.
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3.2.5 Conduct a Web search Web searches are conducted by
staff. Sites searched include P
Cardiosource clinical trials, cli
controlled-trials.com, Google,
Scholar.
3.2.6 Search for studies reported in
languages other than English if
appropriate
PubMed search features allow th
English-only journals. Each CP
clarifies if the searches were l
English language. Articles pub
language other than English b
English may be used in the CP
(e.g., articles in the Canadian
Association Journal often repo
and English). Non-English artic
by the primary language repo
parentheses as cited in the re
3.3 Screen and select studies
3.3.1 Include or exclude studies based on
the protocol’s prespecified criteria
Studies are included or excluded
GWC-determined prespecified
scope of the CPGs and review
influence which studies may b
excluded, as well as studies p
CPGs.
3.3.2 Use observational studies in addition
to RCT to evaluate harms of
interventions
Literature searches focus on pub
only (i.e., RCT followed by obs
studies, meta-analyses, and S
of literature searches focus on
include nonrandomized studie
observational studies, case st
opinion documents).
3.3.3 Use two or more members of the
review team, working independently,
to screen and select studies
CPG sections may be drafted by
who have expertise and in-dep
the subject or by a group of G
a result, relevant studies for e
be screened independently by
members. However, the scree
selection of studies is not exp
multiple members.
3.3.4 Train screeners using written
documentation; test and retest
screeners to improve accuracy and
consistency
GWC committee members are g
orientation to the ACCF/AHA M
Manual (4), as well as in-dept
about how to populate data s
3.3.5 Use one of two strategies to select
studies: 1) read all full-text articles
identified in the search, or 2) screen
titles and abstracts of all articles and
then read the full text of articles
identified in initial screening
Research staff perform literature
document containing the stud
abstract is emailed to the app
member(s). Full-text copies of
are also identified by the rese
sent to GWC members. The fi
relevant studies is the purview
member, so the actual strateg
explicit or mandated.
nd Assessing Individual Studies
thodology Workgroup 3 Proposal
onal trials) are
or possible
w.
The ACCF/AHA CPG methodology is currently compliant.
A search should be performed for observational studies and
unpublished studies, looking for benefits and potential
harm, which would otherwise be missed if only RCT are
reviewed.
Audited data, such as registry data submitted for FDA
approval, may be considered, with due consideration of the
lack of peer review and the importance of an unbiased
audit process.
tronic file of
staff or GWC
standard
kept on file. Text
iteria and key
e CPG
CPG users
literature search
The ACCF/AHA CPG methodology is currently compliant.
ot called out Use of a flowchart should be considered to depict the number
of studies that remain after each stage of the selection
process.
Reasons for exclusion of peer-reviewed RCTs and large
observational trials published in major journals should be
documented in a Web-accessible appendix to the CPG.
Software such as Reference Manager should be potentially
used to document reports, with fields for entering reasons
for exclusion, such as “did not meet fields of interest.”
signed to assist
wever, additional
o assist and work
es/studies in
ll or large
mandate for the
members
e.
Two members of the ERC should extract quantitative or other
critical data from each study. A third individual should be
involved in resolution of discrepancies. These 3 individuals
should be members of the ERC, not the GWC. Their work
should lead to coauthorship of the finished guideline. In
some CPG, there may be more than one 3-person ERC team
for review of evidence in different parts of the CPG,
depending on the scope.
e study are
hereby
peating
The ACCF/AHA CPG methodology is currently compliant.
et of key
WC members for
ndardize data
A standardized data extraction form should be developed that
includes some standard elements and additional elements
unique to the PICO(TS) question.
For broader clinical questions not included in a formal SR, a
similar data extraction form should be developed.
ables undergoes
adoption and
g is done.
The data extraction form should be piloted in a few studies
and then revised.
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3.3.6 Taking account of the risk of bias,
consider including observational
studies to address gaps in the
evidence from RCT on the benefits of
interventions
All trials (e.g., RCT and observati
examined by GWC members f
inclusion in the evidence revie
3.4 Document the search
3.4.1 Provide a line-by-line description of
the search strategy, including the
date of every search for each
database, web browser, etc.
Research staff maintains an elec
searches conducted by either
members. A hard copy of the
literature search form is also
describing literature search cr
search terms is included in th
introduction, thereby allowing
access to the comprehensive
conducted.
3.4.2 Document the disposition of each
report identified including reasons for
their exclusion if appropriate
Excluded studies or reports are n
specifically within the CPG.
3.5 Manage data collection
3.5.1 At a minimum, use two or more
researchers, working independently,
to extract quantitative or other
critical data from each study. For
other types of data, one individual
could extract the data while the
second individual checks for
accuracy and completeness.
Establish a fair procedure for
resolving discrepancies—do not
simply give final decision-making
power to the senior reviewer
Currently 1 staff researcher is as
GWC members on 1 CPG; ho
research staff are available t
in a collaborative manner.
GWC members also review articl
detail individually and in sma
groups. Currently, there is no
number of researchers/GWC
required to review each articl
3.5.2 Link publications from the same
study to avoid including data from
the same study more than once
Multiple publications of the sam
identified by GWC members, t
decreasing the possibility of re
information or data.
3.5.3 Use standard data extraction forms
developed for the specific SR
Evidence tables with a uniform s
characteristics identified by G
each guideline are used to sta
collection.
3.5.4 Pilot-test the data extraction forms
and process
The format of data supplement t
multiple revisions before their
use, but no formal pilot-testin
nd Assessing Individual Studies
thodology Workgroup 3 Proposal
the risk of bias.
essing bias is
ative.
Documentation of the assessment of the risk of bias is
essential.
The system used to assess bias is controversial. Multiple tools
exist, including one in evaluation by ACCF/AHA.
The Cochrane Risk of Bias tool is a qualitative, descriptive tool
used to evaluate individual studies across 6 domains of
bias: selection, performance, detection, attrition, reporting,
and other. In each domain, bias is judged as low, high, or
unclear, with brief supporting comments for each
judgment. There is also a summary judgment for each
study, recommended to be outcome specific.
For each study, the same 2 ERC group members performing
data extraction could simultaneously perform a quality
assessment, with a third individual to adjudicate
differences in data extraction or quality assessment.
A separate risk of bias (separate from the RCT tool) tool is
needed for observational studies and registries.
sing bias is
ative. GWC
licitly assess the
tion, intervention,
The relevance of each study’s populations, interventions,
comparators, outcomes, timing, and setting to the key
clinical question/topic of interest should be assessed.
ventions
e fidelity of the
ns.
For each study, an explicit assessment of the extent to which
the intervention was delivered as planned and the quality of
delivery of the intervention should be included.
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3.6 Critically appraise each study
3.6.1 Systematically assess the risk of
bias, using predefined criteria
GWC expertise is used to assess
The ACCF/AHA system for ass
currently subjective and qualit
3.6.2 Assess relevance of the study’s
populations, interventions, and
outcome measures
The ACCF/AHA system for asses
currently subjective and qualit
members are relied on to imp
relevance of the study popula
and outcome measures.
3.6.3 Assess the fidelity of the
implementation of interventions
The GWC reviews the study inter
implicitly to ensure/assess th
implementation of interventioACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; AHRQ, Agency for Healthcare Research and Quality; CMS, Centers for Medicare and Medicaid Services;
CPG, clinical practice guideline; EPC, evidence-based practice center; ERC, evidence review committee; ESC, European Society of Cardiology; FDA, U.S. Food and Drug Administration; GWC, guideline
writing committee; HRS, Heart Rhythm Society; IOM, Institute of Medicine; LBCT, late-breaking clinical trial; LOE, level of evidence; NCBI, National Center for Biotechnology Information; NCDR, National
Cardiovascular Data Registry; PICO(TS), mnemonic: population, intervention, comparator, outcomes, timing, and setting; RCT, randomized controlled trial; SR, systematic review; and Task Force,
ACCF/AHA Task Force on Practice Guidelines.
sizing the Body of Evidence
rent Methodology Workgroup 4 Proposal
does not systematically
eristics. However, the
icitly judge consistency,
ess when using the
ommendations.
The Workgroup proposes that these IOM-recommended
basic characteristics of quality and elements be
accepted for assessing and describing quality
across studies.
nt of these
ormed on a case basis,
dy analyzed.
The Workgroup recommends the following:
● Standardize the method of assessment and
description of the quality of the body of
evidence across studies.
● Depict qualitative assessment across studies
addressing the key elements for each PICO(TS)
question in a summary table (e.g., similar to
GRADE or other formats [Table 4.1]).
● Where appropriate, provide a risk-of-bias
assessment table across studies (e.g., similar to
the Cochrane format [10]).
● Generate standardized summary and evidence
templates specific to ACCF/AHA requirements.
These elements will be covered.Workgroup 4 Comparison Table
4. Standards for Synthe
IOM Standards and Elements ACCF/AHA Cur
4.1 Use a prespecified method to evaluate the body
of evidence
4.1.1 For each outcome, systematically assess the
following characteristics of the body of
evidence:
● Risk of bias
● Consistency
● Precision
● Directness
● Reporting bias
Currently, the ACCF/AHA
look at these charact
ACCF/AHA does impl
precision, and directn
COR/LOE to write rec
4.1.2 For bodies of evidence that include
observational research, also systematically
assess the following characteristics for each
outcome:
● Dose-response association
● Plausible confounding that would change
the observed effect
● Strength of association
A systematic assessme
characteristics is perf
depending on the stu
sizing the Body of Evidence
rent Methodology Workgroup 4 Proposal
the ACCF/AHA uses
to characterize the level
stimates of the effect of
See above. The IOM standard should be followed.
ed in the form of
ay be presented in the
The Workgroup proposes the following:
● Carry out a qualitative assessment of individual
studies and aggregated studies where appropriate.
● These elements will be described (see also 4.1
above).
● This will require allocation of resources for
additional methodological expertise, because this
exercise is judged to be beyond the expertise and
time commitment expected of GWC members
alone.
● When available, high-quality SRs from reputable
organizations (e.g., the NHLBI, Cochrane, Kaiser, or
EPC) should be used.
● If a new SR is needed, resources will need to be
secured to pursue de novo analysis.
● Notwithstanding these efforts to standardize and
improve the qualitative analysis of bodies of
evidence, every effort should be made to minimize
delays in time to CPG development/revision.
4 ed in the form of
ay be presented in the
The IOM standard should be considered.
ed in the form of
ay be presented in the
The IOM standard should be considered.
ed in the form of
ay be presented in the
The IOM standard should be considered.
ed in the form of
ay be presented in the
The IOM standard should be considered.
The GWC, in conjunction with the Task Force, will
determine when a specific meta-analysis is needed.
When available, high-quality meta-analyses from
reputable organizations (e.g., the NHLBI, Cochrane,
Kaiser, or EPC) should be used.
If a new meta-analysis is needed, resources will need
to be secured to pursue de novo analyses.
Notwithstanding efforts to standardize and improve the
approach to quantitative analyses across studies,
every effort should be made to minimize delays in
time to CPG development/revision.
s for the subject is
ns regarding meta-
d in the text.
This may be described in text. See above.
erformed by GWC
ed meta-analyses are
es used must be
iewed journals, and any
ta-analysis are explained.
With statistical consultation, preferred, acceptable
methods for meta-analysis (including a Bayesian
analysis when appropriate) should be defined in
each instance.
See 4.3 above.
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4.1.3 For each outcome specified in the protocol,
use consistent language to characterize the
level of confidence in the estimates of the
effect of an intervention
By using the COR/LOE,
consistent language
of confidence in the e
an intervention.
4.2 Conduct a qualitative synthesis
4.2.1 Describe the clinical and methodological
characteristics of the included studies,
including their size, inclusion or exclusion of
important subgroups, timeliness, and other
relevant factors
This is currently present
evidence tables but m
text as well.
.2.2 Describe the strengths and limitations of
individual studies and patterns across studies
This is currently present
evidence tables but m
text as well.
4.2.3 Describe, in plain terms, how flaws in the
design or execution of the study (or groups of
studies) could bias the results, explaining the
reasoning behind these judgments
This is currently present
evidence tables but m
text as well.
4.2.4 Describe the relationships between the
characteristics of the individual studies and
their reported findings and patterns across
studies
This is currently present
evidence tables but m
text as well.
4.2.5 Discuss the relevance of individual studies to
the populations, comparisons,
cointerventions, settings, and outcomes or
measures of interest
This is currently present
evidence tables but m
text as well.
4.3 Decide if, in addition to a qualitative analysis,
the SR will include a quantitative analysis
(meta-analysis)
4.3.1 Explain why a pooled estimate might be
useful to decision makers
Reporting meta-analyse
encouraged. Limitatio
analyses are explaine
4.4 If conducting a meta-analysis, then do the
following:
4.4.1 Use expert methodologists to develop,
execute, and peer review the meta-analyses
Meta-analyses are not p
members, but publish
reported. Meta-analys
published in peer-rev
limitations of the me
sizing the Body of Evidence
rent Methodology Workgroup 4 Proposal
t explicitly do this but
rogeneity among study
ines the need to
ndations.
The IOM standard should be considered.
formed. The IOM standard should be considered.
formed. The IOM standard should be considered.
uses COR (I, IIa, IIb, III)/
s other popular systems
The Workgroup recommends the following:
● Retain the current basic ACCF/AHA COR and LOE
structure/nomenclature.
● Standardize how LOE: A, B, C are determined using
a validated ACCF/AHA Evidence Grading Tool (which
is under development).
● Change the wording of LOE to QOE.
● Add a separate category for QOE: E (expert opinion)
and generate specific definitions and examples for
QOE: E.
● Add adjectives that “map” COR/LOE to the NHLBI
(i.e., I [strong]; IIa [moderate]; IIb [weak]; and III
[against]).
● Take every opportunity to align the COR as closely
as possible with the LOE/QOE.
● Provide a chart to map the ACCF/AHA system to
other major grading systems (e.g., Table 4.2).
● In addition:
● Plan for regular review (e.g., annually) of CPG
recommendations and modify as appropriate.
● Develop a list of metrics that should be measured
and assessed.
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4.4.2 Address the heterogeneity among study
effects
The ACCF/AHA does no
implicitly judges hete
effects, which determ
downgrade recomme
4.4.3 Accompany all estimates with measures of
statistical uncertainty
This is not currently per
4.4.4 Assess the sensitivity of conclusions to
changes in the protocol, assumptions, and
study selection (sensitivity analysis)
This is not currently per
Added by Workgroup:
Review ACCF/AHA COR/LOE versus GRADE, NHLBI
methodology (hybrid of GRADE and COR/LOE),
others, and make a recommendation to
Summit: keep our method without change,
change to GRADE or to NHLBI (or another), or
propose a hybrid system.
The ACCF/AHA currently
LOE (A, B, C), wherea
differ.ACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; COR, class of recommendation; CPG, clinical practice guideline; EPC, evidence-based practice center;
GRADE, Grading of Recommendations Assessment, Development and Evaluation; GWC, guideline writing committee; IOM, Institute of Medicine; LOE, level of evidence; NHLBI, National Heart, Lung,
and Blood Institute; PICO(TS), mnemonic: population, intervention, comparator, outcomes, timing and setting; QOE, quality of evidence; SR, systematic review; and Task Force, ACCF/AHA Task Force
on Practice Guidelines.
rting Systematic Reviews
urrent Methodology Workgroup 5 Proposal
le; if the CPG is revised or
ually follows the title of the
wever, ACCF/AHA CPGs are
on formal SR.
Each published SR should have a title that reflects
the CPG for which the evidence is provided. If
the ACCF/AHA conducts an SR that is not
published independently, nevertheless, it will
have a carefully constructed research question
that can be noted on the tables summarizing
the findings of the SR.
utive summary that is
PG and available online. No
y GWC members.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.
utive summary that is
PG and available online.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.Workgroup 5 Comparison Table
5. Standards for Repo
IOM Standards and Elements ACCF/AHA C
5.1 Prepare final report using a structured format
5.1.1 Include a report title Each CPG is given a tit
updated, the title us
previous version. Ho
not generally based
5.1.2 Include an abstract All CPGs have an exec
published with the C
abstract is created b
5.1.3 Include an executive summary All CPGs have an exec
published with the C
rting Systematic Reviews
urrent Methodology Workgroup 5 Proposal
d derivative products are
cardiologists as well as other
s. As a result, no summary is
ublic. CPGs are intended for a
ce and for that reason are
ion of a summary for the lay
lenging.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.
onducted for ACCF/AHA
.5 is not applicable with
nt ACCF/AHA development
CF/AHA CPGs have an
ludes details of the evidence
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes the SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.
onducted for ACCF/AHA
.6 is not applicable for the
evelopment methodology.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used. See Workgroups 3 and 4.
onducted for ACCF/AHA
.7 is not applicable for the
evelopment methodology.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.
onducted for ACCF/AHA
.8 is not applicable for the
evelopment methodology.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.
onducted for ACCF/AHA
.9 is not applicable for the
evelopment methodology.
AHA does not accept outside
has a very robust RWI policy
lable on the Web.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
publishes an SR as a stand-alone document,
relevant IOM Standards and Elements should
be used.
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5.1.4 Include a summary when written for the lay
public
All ACCF/AHA CPGs an
produced mainly for
medical practitioner
created for the lay p
professional audien
very technical. Creat
public could be chal
5.1.5 Include an introduction (rationale and
objectives)
SRs are not generally c
CPGs. Therefore, 5.1
respect to the curre
methodology. All AC
introduction that inc
review.
5.1.6 Include a methods section. Describe the
following:
● Research protocol
● Eligibility criteria (criteria for including and
excluding studies in the systematic review)
● Analytic framework and key questions
● Databases and other information sources
used to identify relevant studies
● Search strategy
● Study selection process
● Data extraction process
● Methods for handling missing information
● Information to be extracted from included
studies
● Methods to appraise the quality of individual
studies
● Summary measures of effect size (e.g., risk
ratio, difference in means)
● Rationale for pooling (or not pooling) results
of included studies
● Methods of synthesizing the evidence
(qualitative and meta-analysis)
● Additional analyses, if done, indicating
which were pre-specified
SRs are generally not c
CPGs. Therefore, 5.1
current ACCF/AHA d
5.1.7 Include a results section. Organize the
presentation of results around key questions.
Describe the following (repeat for each key
question):
● Study selection process
● List of excluded studies and reasons for
their exclusion
● Appraisal of individual studies’ quality
● Qualitative synthesis
● Meta-analysis of results, if performed
(explain rationale for doing one)
● Additional analyses, if done, indicating
which were prespecified
● Tables and figures
SRs are generally not c
CPGs. Therefore, 5.1
current ACCF/AHA d
5.1.8 Include a discussion section. Include the
following:
● Summary of the evidence
● Strengths and limitations of the systematic review
● Conclusions for each key questions
● Gaps in evidence
● Future research needs
SRs are generally not c
CPGs. Therefore, 5.1
current ACCF/AHA d
5.1.9 Include a section describing funding sources
and COI
SRs are generally not c
CPGs. Therefore, 5.1
current ACCF/AHA d
However, the ACCF/
funding for CPG and
for GWC that is avai
rting Systematic Reviews
urrent Methodology Workgroup 5 Proposal
view is managed by ACCF/
.
The ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
conducts its own SR and publishes it, it will be
independently reviewed through the journal’s
review process.
CF/AHA CPGs undergo an
w process that includes
l content experts in addition
orating, and other relevant
s. However, CPGs are not
iew and comment. See
.
The public is able to comment on CPGs through
letters to the editor (postpublication). The
ACCF/AHA has no control over independently
conducted SR, but when the ACCF/AHA
conducts its own SR, external stakeholders and
patient representatives should be included in
this expanded process, and the SR protocol
should be open to public comment.
SRs commissioned by the ACCF and AHA will be
hyperlinked from the CPG and made available
through free public access. SRs performed by
other groups and used as part of the CPG
process may or may not be available for free
public access.
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5.2 Peer review the draft report
5.2.1 Use a third party to manage the peer review
process
ACCF/AHA CPG peer re
AHA document staff
5.2.2 Provide a public comment period for the report
and publicly report on disposition of comments
Currently, while the AC
extensive peer revie
scientific and clinica
to partnering, collab
professional societie
opened to public rev
Workgroups 1 and 2
5.3 Publish the final report in a manner that ensures
free public accessACCF indicates American College of Cardiology Foundation; AHA, American Heart Association; COI, conflict of interest; CPG, clinical practice guideline; GWC, guideline writing committee; IOM, Institute
of Medicine; RWI, relationships with industry and other entities; and SR, systematic review.
